Exhibit 10.3


 


EXHIBIT A


 





 






 


SECURITIES
PURCHASE AGREEMENT


 


and


 


escrow
agreement


 





 






 




    	 		 



     


    

 


MDNA
Life Sciences, Inc.


 


SECURITIES PURCHASE AGREEMENT


 




    	 		 



     


    

 


TABLE OF CONTENTS 





	1.Purchase and Sale of Units	1
	1.1	The Offering; Offering Period	1
	1.2	Closings	2
	1.3	Deliveries	2
	1.4	Purchaser Acknowledgment	3
	1.5	Use of Proceeds	3
	1.6	Defined Terms Used in this Agreement	3
	2.Representations and Warranties of the Company	4
	2.1	Organization, Good Standing, Corporate Power and Qualification	5
	2.2	Capitalization	5
	2.3	Subsidiaries	6
	2.4	Authorization	6
	2.5	Valid Issuance of Securities; No Bad Actors	7
	2.6	Governmental Consents and Filings	7
	2.7	Litigation	8
	2.8	Intellectual Property	8
	2.9	Compliance with Other Instruments	9
	2.10	Agreements; Actions	9
	2.11	Certain Transactions	10
	2.12	Rights of Registration and Voting Rights	10
	2.13	Property	11
	2.14	Financial Statements	11
	2.15	Changes	11
	2.16	Employee Matters	12
	2.17	Tax Returns and Payments	13
	2.18	Insurance	13
	2.19	Employee Agreements	13
	2.20	Permits	14
	2.21	Corporate Documents	14
	2.22	Disclosure	14
	2.23	[Reserved.]	14
	2.24	Environmental and Safety Laws	15
	2.25	Anti-Bribery and Anti-Corruption	15
	2.26	Investment Company Act	15
	2.27	Acknowledgment Regarding Purchasers’ Purchase of Units	15
	2.28	Private Placement	16
	2.29	No Integrated Offering	16
	2.30	Foreign Corrupt Practices	16
	2.31	No Disagreements with Accountants and Lawyers	16
	3.Representations and Warranties of the Purchasers	16
	3.1	Authorization	16
	3.2	Purchase Entirely for Own Account	17
	3.3	Disclosure of Information	17
	3.4	Restricted Securities	17




 



    	 	i	 



     


    

 


TABLE OF CONTENTS

(continued)


 





	3.5	No Public Market	17
	3.6	Legends	17
	3.7	Accredited Investor	18
	3.8	Foreign Investors	18
	3.9	No General Solicitation	18
	3.10	Exculpation Among Purchasers	18
	3.11	Residence	18
	4.Conditions to the Purchasers’ Obligations at Closing	19
	4.1	Representations and Warranties	19
	4.2	Performance	19
	4.3	Compliance Certificate	19
	4.4	Qualifications	19
	4.5	Short-Term Note Conversion	19
	4.6	Investor Waivers	19
	4.7	Waivers/Acknowledgements	19
	4.8	Certificate of Designation	19
	4.9	Secretary’s Certificate	
	4.10	Proceedings and Documents	
	5.Conditions of the Company’s Obligations at Closing	19
	5.1	Representations and Warranties	19
	5.2	Performance	20
	5.3	Qualifications	20
	6.Other Agreements of the Parties	20
	6.1	Piggy-Back Registration Rights	20
	6.2	Conversion Shares and Warrant Shares	23
	6.3	Indemnification of Purchasers	23
	6.4	Reservation of Preferred Stock and Common Stock	24
	6.5	Blue Sky Filings	24
	7.Miscellaneous	24
	7.1	Termination	24
	7.2	Survival of Warranties	24
	7.3	Successors and Assigns	24
	7.4	Governing Law	24
	7.5	Counterparts	24
	7.6	Titles and Subtitles	25
	7.7	Notices	25
	7.8	No Finder’s Fees	25
	7.9	Attorneys’ Fees	25
	7.10	Amendments and Waivers	25
	7.11	Severability	26
	7.12	Delays or Omissions	26
	7.13	Entire Agreement	26
	7.14	Dispute Resolution	26




 



    	 	ii	 



     


    

 





TABLE OF CONTENTS

(continued)



 





	7.15	WAIVER OF JURY TRIAL	26
	7.16	No Commitment for Additional Financing	27
	7.17	Replacement of Securities	27
	7.18	Remedies	27
	7.19	Payment Set Aside	27
	7.20	Independent Nature of Purchasers’ Obligations and Rights	28




 


	Exhibit A -	Certificate of DESIGNATION
	 	 
	Exhibit B -	DISCLOSURE SCHEDULE


 




    	 	iii	 



     


    

 


SECURITIES PURCHASE AGREEMENT


 


THIS SECURITIES PURCHASE
AGREEMENT (this “Agreement”) is made as of the ___ day of _________________, 2018 by and among MDNA Life Sciences,
Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (each
a “Purchaser” and together the “Purchasers”).


 


RECITALS


 


WHEREAS, the Company
desires to sell to the Purchasers units of the Company (each unit, including the components of such unit, a “Unit,”
and collectively the “Units”), with each Unit consisting of (i) one (1) share (each, a “Preferred Share”,
collectively, the “Preferred Shares”) of the Company’s Series A Convertible Preferred Stock (the “Series
A Preferred Stock”) with the preferences, rights and designations set forth in the Certificate of Designation of Preferences,
Rights and Limitations of Series A Convertible Preferred Stock in the form attached as Exhibit A to this Agreement (the
“Certificate of Designation”) and (ii) a seven-year warrant to purchase one share of the Company’s common
stock, $0.001 par value per share (the “Common Stock”), in the form attached to the PPM (each, a “Warrant”,
collectively, the “Warrants”) (the “Offering”);


 


WHEREAS, the Company
is offering a minimum of $100,000 of Units (the “Minimum Offering Amount”) and, a maximum of $2,000,000 of Units
(the “Maximum Offering Amount”); and


 


WHEREAS, the Company
and each Purchaser are executing and delivering this Agreement in reliance upon the exemption from registration afforded by Section
4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation
D”) as promulgated by the United States Securities and Exchange Commission under the Securities Act.


 


NOW, THEREFORE,
in consideration of the foregoing and the representations, warranties, covenants and conditions set forth below, the Company and
each Purchaser, severally and not jointly, intending to be legally bound, hereby agree as follows:


 


		1.	Purchase and Sale of Units.



 


1.1           The
Offering; Offering Period. The purchase and sale of the Units by the Company to the Purchasers shall occur at one or more closings
of the Offering (each a “Closing” and the date of such Closing, the “Closing Date”) to occur during a period
(the “Offering Period”) beginning on January 29, 2018 and ending on the first to occur of: (a) February 28, 2018, subject
to a thirty (30) day extension by the Company without notice to the Purchasers, and (b) the date on which the Maximum Offering
Amount is raised by the Company in the Offering; provided however, that the Offering Period may be terminated by the Company at
any time without prior notice. The Company may conduct multiple Closings during the Offering Period. The initial Closing of the
Offering shall not occur until such time as the Minimum Offering Amount has been deposited with the Escrow Agent in in a non-interest-bearing
escrow account (the “Escrow Account”) (such Closing, the “Initial Closing”). The Company may conduct subsequent
Closings of the Offering (each, a “Subsequent Closing”) until the conclusion of the Offering Period. Purchasers signing
a counterpart signature page to this Agreement as of a Closing Date shall become parties to this Agreement only as of such Closing
Date.


 




    	 	A - 1	 



     


    

 


1.2           Closings.
On each Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and each Purchaser,
severally and not jointly with the other Purchasers (as the case may be), agrees to purchase, the Units indicated on such Purchaser’s
signature page hereto. Prior to each Closing Date, each Purchaser shall deliver to the Company, via wire transfer or a certified
check, in immediately available funds, such Purchaser’s subscription amount as set forth on the signature page hereto (the
“Subscription Amount”), and the Company shall deliver to each Purchaser its respective Units (or the components
of such Units) as determined pursuant to Section 1.3(a) below, and the Company and each Purchaser shall deliver the other
items set forth in Section 1.3 deliverable at the applicable Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 1.3, 4 and 5, as applicable, the applicable Closing shall occur at the offices of Sichenzia Ross Ference
Kesner LLP (“SRFK”) or such other location as the parties shall mutually agree, including remotely via the delivery
of electronic Closing documents.


 


1.3           Deliveries.


 


(a)           On
or prior to any Closing Date (except as otherwise set forth below), the Company shall deliver or cause to be delivered to each
Purchaser participating in the applicable Closing the following:


 


(i)           this
Agreement duly executed by the Company;


 


(ii)          a
certificate for such number of Preferred Shares equal to such Purchaser’s Subscription Amount divided by the Purchase Price,
registered in the name of such Purchaser (such certificate to be delivered within five (5) trading days of the Closing Date); and


 


(iii)          a
Warrant registered in the name of such Purchaser to purchase up to a number of Preferred Shares equal to 100% of the Preferred
Shares purchased by such Purchaser (such Warrant certificate to be delivered within five (5) trading days of the Closing Date).


 


(b)           On
or prior to any Closing Date, each Purchaser participating in the applicable Closing shall deliver or cause to be delivered to
the Company the following:


 


(i)           this
Agreement duly executed by such Purchaser;


 


(ii)          an
Accredited Investor Questionnaire (in the form provided by the Company to the Purchaser), duly executed by the Purchaser;


 


(iii)          the
Escrow Agreement duly executed by such Purchaser; and


 




    	 	A - 2	 



     


    




(iv)         such
Purchaser’s Subscription Amount by wire transfer or certified check to the Escrow Agent.


 


1.4          Purchaser
Acknowledgment. Each Purchaser acknowledges and agrees that such Purchaser’s Subscription Amount shall be held in a non-interest
bearing Escrow Account until such time as the Company conducts a Closing. In the event that the Company does not conduct a Closing
(whether because the Minimum Offering Amount was not raised or otherwise), each Purchaser acknowledges that such Purchaser will
not receive any Units and will instead have returned its Subscription Amount without interest or deduction.


 


1.5          Use
of Proceeds. In accordance with the directions of the Company’s Board of Directors, the Company will use the proceeds
from the sale of the Units to continue development and commercialization of the Company’s mitochondrial-based DNA cancer
detection tests as described in the PPM, to repay outstanding indebtedness, and to provide general working capital for the Company’s
operations.


 


1.6          Defined
Terms Used in this Agreement. In addition to the terms defined above, or elsewhere in this Agreement, the following terms used
in this Agreement shall be construed to have the meanings set forth or referenced below.


 


(a)          “2015
Offering” means the Summer 2015 offering in which the Company privately offered units, with each unit consisting of one
(1) share of Series A Preferred Stock (the “2015 Preferred Stock”) and one (1) warrant (the “2015 Warrant”)
to purchase one share of the Company’s common stock (the “2015 Offering”). The Company has cancelled,
terminated and declared null and void the securities issued pursuant the 2015 Offering.


 


(b)          “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under
common control with such Person, including, without limitation, any general partner, managing member, officer or director of such
Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members
of, or shares the same management company with, such Person.


 


(c)          “Bylaws”
means the Company’s Bylaws, as amended.


 


(d)          “Code”
means the Internal Revenue Code of 1986, as amended.


 


(e)          “Company
Intellectual Property” means all patents, patent applications, trademarks, trademark applications, service marks, service
mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes,
similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing,
licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by the Company in the conduct
of the Company’s business as now conducted and as presently proposed to be conducted.


 


(f)          “Conversion
Shares” means the shares of Common Stock issuable upon conversion of the Preferred Shares.


 




    	 	A - 3	 



     


    

 


(g)          “Escrow
Agent” means Sichenzia Ross Ference Kesner LLP.


 


(h)          “Escrow
Agreement” means that certain Escrow Agreement annexed as Exhibit A to the PPM.


 


(i)          “Knowledge”
including the phrase “to the Company’s knowledge” shall mean the actual knowledge (with the assumption
of reasonable inquiry) of Christopher Mitton, Jennifer Creed, Andrew Harbottle, Robert Poulter.


 


(j)          “Material
Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial
condition, property, prospects or results of operations of the Company.


 


“Person” means any individual, corporation, partnership,
trust, limited liability company, association or other entity.


 


(k)          “Purchase
Price” means $0.55 per Unit.


 


(l)          “PPM”
means the Company’s Private Placement Memorandum, for the Offering of Units.


 


(m)          “Securities”
means the Units, Preferred Shares, Warrants, Conversion Shares, and Warrant Shares.


 


(n)          “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


(o)          “Transaction
Documents” means this Agreement, the Certificate of Designation and the Warrant.


 


(p)          “Warrant
Shares” means the Common Stock issuable upon exercise of the Warrants.


 


2.          Representations
and Warranties of the Company. The Company hereby represents and warrants to each Purchaser that, except as set forth on the
Disclosure Schedule attached as Exhibit B to this Agreement, which exceptions shall be deemed to be part of the representations
and warranties made hereunder, the following representations are true and complete as of the date of the Initial Closing for such
Purchasers that purchase Units at the Initial Closing and as of each Subsequent Closing for each such Purchaser that purchases
Units at such Subsequent Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding
to the numbered and lettered sections contained in this Section 2, and the disclosures in any section of the Disclosure
Schedule shall qualify other sections in this Section 2 only to the extent it is readily apparent from a reading of the
disclosure that such disclosure is applicable to such other sections.


 




    	 	A - 4	 



     


    

 


2.1          Organization,
Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as
presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing
in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.


 


2.2          Capitalization.


 


(a)          The
authorized capital of the Company consists, and will consist immediately prior to the Initial Closing, of:


 


(i)          120,000,000
shares of common stock, $0.001 par value per share (the “Common Stock”), 9,497,440 shares of which are issued
and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have been duly authorized,
are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws.


 


(ii)          20,000,000
shares of blank check preferred stock, $0.001 par value per share (the “Preferred Stock”), 9,090,909 of which
have been designated Series A Preferred Stock, and 4,321,692 of which are issued and outstanding and all of which are reserved
for issuance.


 


(b)          The
Company has reserved 2,200,000 shares of Common Stock for issuance to officers, directors, employees and consultants of the Company
pursuant to its 2015 Stock Incentive Plan duly adopted by the Board of Directors and approved by the Company stockholders (the
“2015 Stock Plan”). Of such reserved shares of Common Stock, no shares of Common Stock have been issued as a
result of the exercise of options granted under the 2015 Stock Plan. Options to purchase 1,300,000 shares of Common Stock have
been granted and options to purchase 1,133,333 shares of Common Stock are currently vested, and 166,667 options are unvested. The
Company has issued restricted stock units to officers, directors, employees and consultants of the Company pursuant to its RSU
Plan duly adopted by the Board of Directors and approved by the Company stockholders (the “RSU Plan”). Of such
issued restricted stock units, no shares of the Company’s Common Stock have been issued pursuant to restricted stock purchase
agreements, of such restricted stock units, 3,479,841 are vested, and 475,000 are unvested. The Company has furnished to the Purchasers
complete and accurate copies of the 2015 Stock Plan and RSU Plan and forms of agreements used thereunder.


 


(c)          Section
2.2(c) of the Disclosure Schedule sets forth the capitalization of the Company immediately following the Initial Closing including
the number of shares of the following: (i) issued and outstanding Common Stock; (ii) granted stock options, including
vesting schedule and exercise price; (iii) shares of Common Stock reserved for future award grants under the 2015 Stock Plan;
(iv) warrants or stock purchase rights, if any; and (v) shares of Common Stock reserved for issuance upon conversion of Preferred
Stock and warrants. Except for the Securities and the securities and rights described in Section 2.2(b) of this Agreement
and Section 2.2(c) of the Disclosure Schedule, there are no outstanding options, warrants, rights (including conversion
or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire
from the Company any shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock.


 




    	 	A - 5	 



     


    

  


(d)          Except
as described in Section 2.2(d) of the Disclosure Schedule, none of the Company’s stock purchase agreements or stock
option documents contains a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting
provisions or other terms of such agreement or understanding upon the occurrence of any event or combination of events, including
without limitation in the case where the Company’s Stock Plan is not assumed in an acquisition. The Company has never adjusted
or amended the exercise price of any stock options previously awarded, whether through amendment, cancellation, replacement grant,
repricing, or any other means. The Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital
stock.


 


(e)          409A. The
Company believes in good faith that any “nonqualified deferred compensation plan” (as such term is defined under Section
409A(d)(1) of the Code and the guidance thereunder) under which the Company makes, is obligated to make or promises to make,
payments (each, a “409A Plan”) complies in all material respects, in both form and operation, with the requirements
of Section 409A of the Code and the guidance thereunder. To the Company’s knowledge, no payment to be made under any 409A
Plan is, or will be, subject to the penalties of Section 409A(a)(1) of the Code.


 


2.3          Subsidiaries.
The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust,
joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint
venture, partnership or similar arrangement.


 


2.4          Authorization.
All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize the
Company to enter into the Agreement, and to issue the Units, the Preferred Shares and the Warrants at the Closing and to issue
the Conversion Shares upon conversion of the Preferred Shares in accordance with the terms of the Certificate of Designation and
the Warrant Shares upon exercise of the Warrants in accordance with their terms and payment of the exercise price therefor has
been taken or will be taken prior to the Closing. All action on the part of the officers of the Company necessary for the execution
and delivery of the Transaction Documents, the performance of all obligations of the Company under the Transaction Documents to
be performed as of the Closing, and the issuance and delivery of the Preferred Shares and Warrants has been taken or will be taken
prior to the Closing. The Agreement, when executed and delivered by the Company, shall constitute valid and legally binding obligations
of the Company, enforceable against the Company in accordance with their respective terms except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or
affecting the enforcement of creditors’ rights generally, or (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies.


 




    	 	A - 6	 



     


    

  


2.5          Valid
Issuance of Securities; No Bad Actors.


 


(a)          The
Units, Preferred Shares and Warrants, when issued, sold and delivered in accordance with the terms and for the consideration set
forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions
on transfer under the Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by
a Purchaser. Assuming the accuracy of the representations of the Purchasers in Section 3 of this Agreement and subject to
the filings described in Section 2.6 below, the Units, Preferred Shares and Warrants will be issued in compliance with all
applicable federal and state securities laws. The Conversion Shares have been duly reserved for issuance, and upon issuance in
accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable and free of restrictions
on transfer other than restrictions on transfer under the Agreement, applicable federal and state securities laws and liens or
encumbrances created by or imposed by a Purchaser. Based in part upon the representations of the Purchasers in Section 3
of this Agreement, and subject to Section 2.6 below, the Conversion Shares upon issuance in accordance with the terms of
the Certificate of Designation will be issued in compliance with all applicable federal and state securities laws. The Warrant
Shares have been duly reserved for issuance, and upon issuance in accordance with the terms of the Warrants and payment of the
exercise price therefor, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions
on transfer under the Agreement, applicable federal and state securities laws and liens or encumbrances created by or imposed by
a Purchaser. Based in part upon the representations of the Purchasers in Section 3 of this Agreement, and subject to Section
2.6 below, the Warrant Shares upon issuance in accordance with the terms of the Warrants and payment of the exercise price
therefor will be issued in compliance with all applicable federal and state securities laws.


 


(b)          None
of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the Offering hereunder, or, to the Company’s knowledge, any beneficial owner (as that term is defined in Rule 13d-3 under
the Securities Exchange Act of 1934, as amended (the “Exchange”)) of 20% or more of the Company’s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”
and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a
Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any
Issuer Covered Person is subject to a Disqualification Event.


 


2.6          Governmental
Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section 3 of this Agreement, no
consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions
contemplated by this Agreement, except for filings pursuant to Regulation D and applicable state securities laws, which have
been made or will be made in a timely manner.


 




    	 	A - 7	 



     


    

  


2.7          Litigation.
Except as disclosed on Section 2.7 of the Disclosure Schedule, there is no claim, action, suit, proceeding, arbitration,
complaint, charge or investigation pending or to the Company’s knowledge, currently threatened (i) against the Company or
any officer, or director of the Company arising out of their employment or board relationship with the Company; (ii) that questions
the validity of the Transaction Documents or the right of the Company to enter into them, or to consummate the transactions contemplated
by the Transaction Documents; or (iii) to the Company’s knowledge, that would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect. Neither the Company nor, to the Company’s knowledge, any of its officers,
or directors is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court
or government agency or instrumentality (in the case of officers or directors, such as would affect the Company). There is no action,
suit, proceeding or investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without
limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the
Company) involving the prior employment of any of the Company’s employees, their services provided in connection with the
Company’s business, any information or techniques allegedly proprietary to any of their former employers or their obligations
under any agreements with prior employers.


 


2.8          Intellectual
Property. The Company owns or possesses the right to use, or believes it can acquire on commercially reasonable terms sufficient
legal rights to use, all Company Intellectual Property without any known conflict with, or infringement of, the rights of others.
To the Company’s knowledge, no product or service marketed or sold (or proposed to be marketed or sold) by the Company violates
or will violate any license or infringes or will infringe any intellectual property rights of any other party. Other than with
respect to commercially available software products under standard end-user object code license agreements, there are no outstanding
options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual
Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any
other Person. The Company has not received any communications alleging that the Company has violated, or by conducting its business,
would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, mask works or other proprietary
rights or processes of any other Person. The Company has obtained and possesses valid licenses to use all of the software programs
present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided
to its employees for their use in connection with the Company’s business. It will not be necessary to use any inventions
of any of its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Company.
Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the
Company’s business as now conducted and as presently proposed to be conducted. Section 2.8 of the Disclosure Schedule lists
all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, tradenames, copyright,
and licenses to and under any of the foregoing that constitutes Company Intellectual Property. The Company has not embedded any
open source, copyright or community source code in any of its products generally available or in development, including but not
limited to any libraries or code, software, technologies or other materials that are licensed or distributed under any General
Public License, Lesser General Public License or similar license arrangement. For purposes of this Section 2.8, the Company shall
be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right.


 




    	 	A - 8	 



     


    

  


2.9          Compliance
with Other Instruments. Except as disclosed on Section 2.9 of the Disclosure Schedule, the Company is not in violation or default,
and the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated
thereby will not cause a violation or default (i) of any provisions of the Company’s Certificate of Incorporation, as amended
(the “Certificate of Incorporation”), or the Company’s Bylaws, (ii) of any instrument, judgment, order,
writ or decree, (iii) under any note, indenture or mortgage, (iv) under any lease, agreement, contract or purchase order to which
it is a party or by which it is bound, or (v) of any provision of federal or state statute, rule or regulation applicable to the
Company, the violation of which would have a Material Adverse Effect. The execution, delivery and performance of the Transaction
Documents and the consummation of the transactions contemplated by the Transaction Documents will not result in any such violation
or be in conflict with or constitute, with or without the passage of time and giving of notice, either (1) a default under any
such provision, instrument, judgment, order, writ, decree, contract or agreement or (2) an event which results in the creation
of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any
material permit or license applicable to the Company.


 


2.10          Agreements;
Actions.


 


(a)          Except
for the Transaction Documents and as disclosed on Section 2.10(a) of the Disclosure Schedule, there are no agreements, understandings,
instruments, contracts or proposed transactions to which the Company is a party or by which it is bound that involve (i) obligations
(contingent or otherwise) of, or payments to, the Company in excess of $100,000; (ii) the license of any patent, copyright, trademark,
trade secret or other proprietary right to or from the Company, (ii) the grant of rights to manufacture, produce, assemble,
license, market, or sell its products to any other Person that limit the Company’s exclusive right to develop, manufacture,
assemble, distribute, market or sell its products, or (iii) indemnification by the Company with respect to infringements of proprietary
rights.


 


(b)          
Except as disclosed in the PPM and as disclosed on Section 2.10(b) of the Disclosure Schedule, the Company has not (i) declared
or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock,
(ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $10,000 or in
excess of $25,000 in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for travel
expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory
in the ordinary course of business. For the purposes of this Section 2.10, all indebtedness, liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe
are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such Section.


 


(c)          The
Company is not a guarantor or indemnitor of any indebtedness of any other Person.


 




    	 	A - 9	 



     


    

  


(d)          Except
as disclosed in Schedule 2.15, the Company is not in default with respect to any indebtedness, and the Company does not intend
to incur any other debts which it will not be able repay as such debts become due. Based on the financial condition of the Company
as of the applicable Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Units
hereunder representing the Minimum Offering Amount, the Company anticipates being able to continue its business operations for
approximately twelve (12) months from the applicable Closing Date. The Company has no Knowledge of any facts or circumstances which
lead it to believe that, assuming the sale of the Minimum Offering Amount, it will file for reorganization or liquidation under
the bankruptcy or reorganization laws of any jurisdiction within one year from the applicable Closing Date.


 


2.11          Certain
Transactions.


 


(a)          Other
than (i) standard employee benefits generally made available to all employees, (ii) standard director and officer indemnification
agreements approved by the Board of Directors, and (iii) the purchase of shares of the Company’s capital stock and the issuance
of options to purchase shares of the Company’s Common Stock, in each instance, approved in the written minutes of the Board
of Directors, there are no agreements, understandings or proposed transactions between the Company and any of its officers, directors,
consultants or employees, or any Affiliate thereof.


 


(b)          Except
as disclosed in Section 2.11(b) of the Disclosure Schedule, the Company is not indebted, directly or indirectly, to any
of its directors, officers or employees or to their respective spouses or children or to any Affiliate of any of the foregoing,
other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation
expenses and for other customary employee benefits made generally available to all employees. None of the Company’s directors,
officers or employees, or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly,
indebted to the Company or, to the Company’s knowledge, have any (i) material commercial, industrial, banking, consulting,
legal, accounting, charitable or familial relationship with any of the Company’s customers, suppliers, service providers,
joint venture partners, licensees and competitors, (ii) direct or indirect ownership interest in any firm or corporation with which
the Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with
the Company except that directors, officers, employees or stockholders of the Company may own stock in (but not exceeding two percent
(2%) of the outstanding capital stock of) publicly traded companies that may compete with the Company; or (iii) financial interest
in any material contract with the Company. The Company has the outstanding indebtedness to noteholders and lenders disclosed in
Section 2.11(b) of the Disclosure Schedule.


 


2.12          Rights
of Registration and Voting Rights. Except as disclosed in the PPM and except for the rights provided to the Purchasers pursuant
to Section 6.1 hereto, the Company is not under any obligation to register under the Securities Act any of its currently
outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. To the Company’s
knowledge, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company.


 




    	 	A - 10	 



     


    

  


2.13          Property.
Except as disclosed in Section 2.13 of the Disclosure Schedule, the property and assets that the Company owns are free and
clear of all mortgages, deeds of trust, liens, loans and encumbrances, except for statutory liens for the payment of current taxes
that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair
the Company’s ownership or use of such property or assets. With respect to the property and assets it leases, the Company
is in compliance with such leases and, to the Company’s knowledge, holds a valid leasehold interest free of any liens, claims
or encumbrances other than those of the lessors of such property or assets. The Company does not own any real property.


 


2.14          Financial
Statements. To the Knowledge of the Company, the Company has no liability or obligation, absolute or contingent (individually
or in the aggregate), except (i) obligations and liabilities incurred after the date of formation in the ordinary course of business
that are not material, individually or in the aggregate, and (ii) obligations under contracts made in the ordinary course of business
that would not be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles.


 


2.15          Changes.
Except as disclosed on Section 2.15 of the Disclosure Schedule or in the PPM, since the Company’s inception there
has not been:


 


(a)          any
change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Company’s
financial statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse
Effect;


 


(b)          any
damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;


 


(c)          any
waiver or compromise by the Company of a valuable right or of a material debt owed to it;


 


(d)          any
satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;


 


(e)          any
material change to a material contract or agreement by which the Company or any of its assets is bound or subject;


 


(f)          any
material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;


 


(g)          any
mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties
or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially
impair the Company’s ownership or use of such property or assets;


 




    	 	A - 11	 



     


    

  


(h)          any
loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their
immediate families, other than travel advances and other advances made in the ordinary course of its business;


 


(i)           any
declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct
or indirect redemption, purchase, or other acquisition of any of such stock by the Company;


 


(j)           any
sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material Adverse
Effect;


 


(k)          receipt
of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;


 


(l)           to
the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s
industry generally, that could reasonably be expected to result in a Material Adverse Effect; or


 


(m)          any
arrangement or commitment by the Company to do any of the things described in this Section 2.15.


 


2.16         Employee
Matters.


 


(a)          To
the Company’s knowledge, none of its employees is obligated under any contract (including licenses, covenants or commitments
of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would
materially interfere with such employee’s ability to promote the interest of the Company or that would conflict with the
Company’s business. Neither the execution or delivery of the Transaction Documents, nor the carrying on of the Company’s
business by the employees of the Company, nor the conduct of the Company’s business as now conducted and as presently proposed
to be conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions, or provisions
of, or constitute a default under, any contract, covenant or instrument under which any such employee is now obligated.


 


(b)          Except
as disclosed in Section 2.16(b) of the Disclosure Schedule, the Company has not accrued payments to any of its employees,
consultants, or independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service
performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors.
The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with
other laws related to employment, including those related to wages, hours, worker classification and collective bargaining. The
Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental
entity all amounts required to be withheld from employees of the Company and is not liable for any arrears of wages, taxes, penalties
or other sums for failure to comply with any of the foregoing.


 




    	 	A - 12	 



     


    

  


(c)          To
the Company’s knowledge, no officer of the Company intends to terminate employment with the Company or is otherwise likely
to become unavailable to continue as an officer of the Company, nor does the Company have a present intention to terminate employment
of any of the foregoing. The employment of each employee of the Company is terminable at the will of the Company. Except as set
forth in Section 2.16(c) of the Disclosure Schedule or as required by law, upon termination of the employment of any such
employees, no severance or other payments will become due. Except as set forth in Section 2.16(c) of the Disclosure Schedule,
the Company has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection
with the termination of employment services.


 


(d)          The
Company has not made any representations regarding equity incentives to any officer, employee, director or consultant that are
inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s board of directors.


 


(e)          Except
as disclosed on Section 2.16(e) of the Disclosure Schedule, the Company has no employment, consulting or similar agreement
that obligates the Company to pay any person for services.


 


(f)          Section
2.16(f) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by the Company,
or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974,
as amended (“ERISA”). The Company has made all required contributions and has no liability to any such employee
benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA, and has complied
in all material respects with all applicable laws for any such employee benefit plan.


 


2.17          Tax
Returns and Payments. Except as disclosed on Section 2.17 of the Disclosure Schedule, (i) there are no federal, state,
county, local or foreign taxes due and payable by the Company, (ii) there are no accrued and unpaid federal, state, country, local
or foreign taxes of the Company which are due, whether or not assessed or disputed, (iii) there have been no examinations or audits
of any tax returns or reports by any applicable federal, state, local or foreign governmental agency and (iv) the Company has duly
and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect
no waivers of applicable statutes of limitations with respect to taxes for any year.


 


2.18          Insurance.
The Company and its business and assets are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as are prudent and customary in the businesses in which the Company is engaged.


 


2.19          Employee
Agreements. Each current and former employee, consultant and officer of the Company has executed an agreement with the Company
regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Purchasers
(the “Non-Disclosure and Development Agreements”). No current or former employee has excluded works or inventions
from his or her assignment of inventions pursuant to such Non-Disclosure and Development Agreements. Each current and former employee
has executed a non-competition agreement substantially in the form or forms delivered to counsel for the Purchasers. The Company
is not aware that any of its employees is in violation of any agreement covered by this Section 2.19.


 




    	 	A - 13	 



     


    

  


2.20          Permits.


 


(a)          The
Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack of
which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material respect under
any of such franchises, permits, licenses or other similar authority.


 


(b)          The
Company is in compliance with all applicable federal, state or local laws and regulations in all material respects with regard
to its test products and product candidates (each such product or product candidate, a “Test Product”) identified in
the PPM. There is no pending, completed or, to the Company's Knowledge, threatened, action (including any lawsuit, arbitration,
or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company, and the Company
has not received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests
the ability of the Company to conduct any of its present or contemplated activities with respect to any Test Product (including,
without limitation, those disclosed in the PPM), (ii) withdraws its authorization for any Test Product, (iii) imposes a clinical
hold on any clinical investigation by or on behalf of the Company; (iv) enjoins production at any facility of the Company, (v)
enters or proposes to enter into a consent decree of permanent injunction with the Company, or (vi) otherwise alleges any violation
of any laws, rules or regulations by the Company, and which, either individually or in the aggregate, would reasonably be expected
to have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in
all material respects in accordance with all applicable federal, state and local laws, rules and regulations.


 


2.21         Corporate
Documents. The Certificate of Incorporation and Bylaws of the Company are in the form provided to the Purchasers. The copy
of the minute books of the Company contains minutes of all meetings of directors and stockholders and all actions by written consent
without a meeting by the directors and stockholders since the date of incorporation and accurately reflects in all material respects
all actions by the directors (and any committee of directors) and stockholders with respect to all transactions referred to in
such minutes.


 


2.22         Disclosure.
Neither the PPM, nor any representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure
Schedule, and no certificate furnished or to be furnished to Purchasers at any Closing contains any untrue statement of a material
fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in
light of the circumstances under which they were made.


 


2.23         [Reserved.]


 




    	 	A - 14	 



     


    

  


2.24         Environmental
and Safety Laws. Except as could not reasonably be expected to have a Material Adverse Effect, to the best of the Company’s
knowledge (a) the Company is and has been in compliance with all Environmental Laws; (b) there has been no release or
to the Company’s knowledge threatened release of any pollutant, contaminant or toxic or hazardous material, substance or
waste or petroleum or any fraction thereof (each a “Hazardous Substance”), on, upon, into or from any site currently
or heretofore owned, leased or otherwise used by the Company; (c) there have been no Hazardous Substances generated by the
Company that have been disposed of or come to rest at any site that has been included in any published U.S. federal, state or local
“superfund” site list or any other similar list of hazardous or toxic waste sites published by any governmental authority
in the United States; and (d) there are no underground storage tanks located on, no polychlorinated biphenyls (“PCBs”)
or PCB-containing equipment used or stored on, and no hazardous waste as defined by the Resource Conservation and Recovery Act,
as amended, stored on, any site owned or operated by the Company, except for the storage of hazardous waste in compliance with
Environmental Laws. The Company has made available to the Purchasers true and complete copies of all material environmental records,
reports, notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies and environmental
studies or assessments. For purposes of this Section 2.24, “Environmental Laws” means any law, regulation,
or other applicable requirement relating to (a) releases or threatened release of Hazardous Substance; (b) pollution or protection
of employee health or safety, public health or the environment; or (c) the manufacture, handling, transport, use, treatment,
storage, or disposal of Hazardous Substances.


 


2.25        Anti-Bribery
and Anti-Corruption. The Company represents and warrants that neither it, nor any of its directors, officers, agents, stockholders
or employees acting on behalf of the Company, has taken any action that will cause the Purchaser or their affiliates to be in breach
of any applicable laws for the prevention of fraud, bribery, corruption, racketeering, money laundering or terrorism, including
but not limited to the U.S. Foreign Corrupt Practices Act, as amended, the Canadian Corruption of Foreign Officials Act, as amended,
and the U.K. Bribery Act 2010 (“Anti-Corruption Laws”). The Company agrees that it has not, and covenants that
it will not, in connection with the conduct of its business activities, promise, authorize, ratify or offer to make, or take any
act in furtherance of any payment, contribution, gift, reimbursement or other transfer of anything of value, or any solicitation,
directly or indirectly: (i) to any individual including government officials; or (ii) to an intermediary for payment to any individual
including government officials; or (iii) to any political party for the purpose or effect of public or commercial bribery, acceptance
of or acquiescence in extortion, kickbacks or other unlawful, illegal or improper means. The Company has not, nor to the knowledge
of the Company, have any of the Company’s directors, officers, agents, stockholders or employees acting on behalf of the
company established or maintained any unrecorded fund or asset for any purpose, or has made any false or artificial entries on
any of its books or records for any reason.


 


2.26         Investment
Company Act. The Company is not, and after the receipt and application of the proceeds of the financing contemplated by this
Agreement will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended.


 


2.27         Acknowledgment
Regarding Purchasers’ Purchase of Units. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to
each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.


 




    	 	A - 15	 



     


    

  


2.28         Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3, no registration
under the Securities Act is required for the offer and sale of the Units by the Company to the Purchasers as contemplated hereby.


 


2.29         No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Units to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration
of any such securities under the Securities Act.


 


2.30         Foreign
Corrupt Practices. Neither the Company nor to the Knowledge of the Company, any agent or other person acting on behalf of the
Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses
related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or
employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any
contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.


 


2.31         No
Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and
the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s ability
to perform any of its obligations under any of the Transaction Documents.


 


		3.	Representations and Warranties of the Purchasers.



 


Each Purchaser hereby represents and warrants
to the Company, severally and not jointly, that:


 


3.1          Authorization.
The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser,
will constitute valid and legally binding obligations of the Purchaser, enforceable in accordance with its terms, except as limited
by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application
affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies.


 




    	 	A - 16	 



     


    

  


3.2          Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to
the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Units to be acquired
by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting
any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the
Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the Units. The Purchaser has not been formed for the
specific purpose of acquiring the Units.


 


3.3          Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs
and the terms and conditions of the offering of the Units with the Company’s management and has had an opportunity to review
the Company’s facilities. The foregoing, however, does not limit or modify the representations and warranties of the Company
in Section 2 of this Agreement or the right of the Purchasers to rely thereon.


 


3.4          Restricted
Securities. The Purchaser understands that the Units (including the components thereof) have not been registered under the
Securities Act or any state securities law, by reason of a specific exemption from the registration provisions of the Securities
Act and state securities law which depends upon, among other things, the bona fide nature of the investment intent and the accuracy
of the Purchaser’s representations as expressed herein. The Purchaser understands that the Units (including the components
thereof) are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to
these laws, the Purchaser must hold the Units (including the components thereof) indefinitely unless they are registered with the
Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification
requirements is available. The Purchaser acknowledges that if an exemption from registration or qualification is available, it
may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the
Units (including the components thereof), and on requirements relating to the Company which are outside of the Purchaser’s
control, and which the Company is under no obligation and may not be able to satisfy.


 


3.5          No
Public Market. The Purchaser understands that no public market now exists for the any of the Securities, and that the Company
has made no assurances that a public market will ever exist for the Securities.


 


3.6          Legends.
The Purchaser understands that the Securities and any securities issued in respect of or exchange for the Securities, may be notated
with one or all of the following legends:


 


(a)          “THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”


 




    	 	A - 17	 



     


    

  


(b)          Any
legend set forth in, or required by, the other Transaction Documents.


 


(c)          Any
legend required by the securities laws of any state to the extent such laws are applicable to the Securities represented by the
certificate, instrument, or book entry so legended.


 


3.7          Accredited
Investor. Subject to Section 3.8, the Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D.


 


3.8          Foreign
Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the Units or any use of this Agreement, including (i) the legal requirements within its jurisdiction
for the purchase of the Units, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental
or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant
to the purchase, holding, redemption, sale, or transfer of the Units (including the components thereof). The Purchaser’s
subscription and payment for and continued beneficial ownership of the Units (including the components thereof) will not violate
any applicable securities or other laws of the Purchaser’s jurisdiction.


 


3.9          No
General Solicitation. Neither the Purchaser, nor to its knowledge, any of its officers, directors, employees, agents, stockholders
or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation,
or (b) published any advertisement in connection with the offer and sale of the Units.


 


3.10          Exculpation
Among Purchasers. The Purchaser acknowledges that it is not relying upon any Person, other than the Company and its officers
and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither any Purchaser nor
the respective controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any
other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Units.


 


3.11          Residence.
If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of the Purchaser
set forth on such Purchaser’s signature page; if the Purchaser is a partnership, corporation, limited liability company or
other entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address
or addresses of the Purchaser set forth on such Purchaser’s signature page.


 




    	 	A - 18	 



     


    

  


4.             Conditions
to the Purchasers’ Obligations at Closing. The obligations of each Purchaser to purchase Units at any Closing (unless
otherwise indicated) are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise
waived:


 


4.1          Representations
and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct
in all respects as of such Closing.


 


4.2          Performance.
The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement
that are required to be performed or complied with by the Company on or before such Closing.


 


4.3          Compliance
Certificate. The Company shall have delivered to the Purchasers at the Closing a certificate executed on behalf of the Company
by its Chief Executive Officer certifying that the conditions specified in Sections 4.1 and 4.2 have been fulfilled.


 


4.4          Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any
state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be obtained
and effective as of such Closing.


 


4.5          Reserved.


 


4.6          Certificate
of Designation. The Certificate of Designation shall be in full force and effect as of such Closing.


 


4.7          Secretary’s
Certificate. The Company shall have delivered to the Purchasers at such Closing a certificate executed on behalf of the Company
by its Secretary (i) certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated
by this Agreement and the other Transaction Documents, including the adoption and filing of the Certificate of Designation, and
the issuance of the Securities, (ii) certifying and providing copies of the current versions of the Certificate of Incorporation,
including the Certificate of Designation, and Bylaws of the Company and (iii) certifying as to the signatures and authority of
persons signing the Transaction Documents and related documents on behalf of the Company.


 


4.8          Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at such Closing and all
documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and each Purchaser (or its
counsel) shall have received all such counterpart original and certified or other copies of such documents as reasonably requested.
Such documents may include good standing certificates.


 


5.             Conditions
of the Company’s Obligations at Closing. The obligations of the Company to sell Units to any Purchaser at any Closing
are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived:


 


5.1          Representations
and Warranties. The representations and warranties of such Purchaser contained in Section 3 shall be true and correct in all
respects as of such Closing.


 




    	 	A - 19	 



     


    

 


 


5.2          Performance.
The Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement
that are required to be performed or complied with by such Purchaser on or before such Closing.


 


5.3          Qualifications.
All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any
State that are required in connection with the lawful issuance and sale of the Units pursuant to this Agreement shall be obtained
and effective as of the Closing.


 


		6.	Other Agreements of the Parties.



 


6.1          Piggy-Back
Registration Rights.


 


(a)          If,
at any time on or after the Closing, the Company proposes to file any Registration Statement under the Securities Act (a “Registration
Statement”) with respect to any offering of equity securities, or securities or other obligations exercisable or exchangeable
for, or convertible into, equity securities, by the Company for its own account or for shareholders of the Company for their account
(or by the Company and by shareholders of the Company), then the Company shall (x) give written notice of such proposed filing
to the holders of Securities appearing on the books and records of the Company as such a holder as soon as practicable but in no
event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe the
amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name
of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to the holders of Securities in such
notice the opportunity to register the sale of such number of Securities as such holders may request in writing within five (5)
days following receipt of such notice (a “Piggy-Back Registration”). The Company shall use commercially reasonable
best efforts to cause such Securities to be included in such registration and shall cause the managing underwriter or underwriters
of a proposed underwritten offering to permit the Securities requested to be included in a Piggy-Back Registration on the same
terms and conditions as any similar securities of the Company and to permit the sale or other disposition of such Securities in
accordance with the intended method(s) of distribution thereof. All holders of Securities proposing to distribute their securities
through a Piggy-Back Registration that involves an underwriter or underwriters shall enter into an underwriting agreement in customary
form with the underwriter or underwriters selected for such Piggy-Back Registration. Notwithstanding anything to the contrary in
this Section 6.1, the Company shall not be required to register such Securities pursuant to this Section 6.1 that
are eligible for resale pursuant to Rule 144 promulgated under the Securities Act or that are the subject of a then effective Registration
Statement.


 


(b)          Any
holder of Securities may elect to withdraw such holder’s request for inclusion of Securities in any Piggy-Back Registration
by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration Statement. The
Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual
obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding
any such withdrawal, the Company shall pay all expenses incurred by the holders of Securities in connection with such Piggy-Back
Registration (including but not limited to any legal fees).


 




    	 	A - 20	 



     


    

  


(c)          The
Company shall notify the holders of Securities at any time when a prospectus relating to such holder’s Securities is required
to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result of which, the prospectus
included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state any
material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing. At the request of such holder, the Company shall also prepare, file and furnish to such holder a reasonable number
of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers
of the Securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing. The
holders of Securities shall not offer or sell any Securities covered by the Registration Statement after receipt of such notification
until the receipt of such supplement or amendment.


 


(d)          The
Company may request a holder of Securities to furnish the Company such information with respect to such holder and such holder’s
proposed distribution of the Securities pursuant to the Registration Statement as the Company may from time to time reasonably
request in writing or as shall be required by law or by the Commission in connection therewith, and such holders shall furnish
the Company with such information.


 


(e)          All
fees and expenses incident to the performance of or compliance with this Section 6.1 by the Company shall be borne by the
Company whether or not any Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing
sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses
of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Securities
and Exchange Commission, (B) with respect to filings required to be made with any trading market on which the Common Stock or other
Securities are then listed for trading, (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to
by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with
Blue Sky qualifications or exemptions of the Securities) and (D) with respect to any filing that may be required to be made by
any broker through which a holder of Securities intends to make sales of Securities with FINRA, (ii) printing expenses, (iii) messenger,
telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other persons or entities retained by the Company in
connection with the consummation of the transactions contemplated by this Section 6.1. In addition, the Company shall be
responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this
Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting
duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Securities on
any securities exchange as required hereunder.


 




    	 	A - 21	 



     


    

  


(f)          The
Company and its successors and assigns shall indemnify and hold harmless each Purchaser, each holder of Securities, the officers,
directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of
a person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each individual or entity
who controls each Purchaser or any such holder of Securities (within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other individuals
or entities with a functionally equivalent role of a person holding such titles, notwithstanding a lack of such title or any other
title) of each such controlling individual or entity (each, an “Indemnified Party”), to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1)
any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any related prospectus or any
form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in
the case of any such prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading
or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or
any rule or regulation thereunder, in connection with the performance of its obligations under this Section 6.1, except
to the extent, but only to the extent, that such untrue statements or omissions are based upon information regarding a Purchaser
or such holder of Securities furnished to the Company by such party for use therein. The Company shall notify each Purchaser and
each holder of Securities promptly of the institution, threat or assertion of any proceeding arising from or in connection with
the transactions contemplated by this Section 6.1 of which the Company is aware. If the indemnification hereunder is unavailable
to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then the Company shall contribute
to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of
the Company and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well
as any other relevant equitable considerations. The relative fault of the Company and Indemnified Party shall be determined by
reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material
fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, the
Company or the Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed
to include any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any proceeding to
the extent such party would have been indemnified for such fees or expenses if the indemnification provided for herein was available
to such party in accordance with its terms. It is agreed that it would not be just and equitable if contribution pursuant to this
Section 6.1(f) were determined by pro rata allocation or by any other method of allocation that does not take into account
the equitable considerations referred to in the immediately preceding sentence. Notwithstanding the provisions of this Section
6.1(f), neither the Purchaser nor any holder of Securities shall be required to contribute, in the aggregate, any amount in
excess of the amount by which the net proceeds actually received by such party from the sale of all of their Registrable Securities
pursuant to such Registration Statement or related prospectus exceeds the amount of any damages that such party has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.


 




    	 	A - 22	 



     


    

  


6.2          Conversion
Shares and Warrant Shares. If all or any portion of a Preferred Share is converted or a Warrant is exercised at a time when
there is an effective registration statement to cover the issuance or resale of the Conversion Shares and/or Warrant Shares, if
the Preferred Share is converted at a time where Rule 144 is available for the resale of such Conversion Shares, or if the Warrant
is exercised via cashless exercise pursuant to the terms of the Warrant such that Rule 144 is available for the resale of such
Warrant Shares, the Conversion Shares and/or Warrant Shares issued pursuant to any such conversion or exercise shall be issued
free of all legends.


 


6.3          Indemnification
of Purchasers. Subject to the provisions of this Section 6.3, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such
Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may
be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall
have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not
be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s
prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a
loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 6.3 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or are incurred, subject to recoupment if the Purchaser Party is found to not be entitled
to indemnification for such amount(s). The indemnity agreements contained herein shall be in addition to any cause of action or
similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to
law.


 




    	 	A - 23	 



     


    

  


6.4          Reservation
of Preferred Stock and Common Stock. The Company has reserved and will keep available at all times, free of preemptive rights,
a sufficient number of shares of Preferred Stock and Common Stock for the purpose of enabling the Company to issue Securities pursuant
to this Agreement, the Certificate of Designation and the Warrant.


 


6.5          Blue
Sky Filings. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an
exemption for, or to qualify the Units for, sale to the Purchasers at the applicable Closing under applicable securities or “Blue
Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.


 


		7.	Miscellaneous.



 


7.1          Termination.
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the applicable
Closing in which such Purchaser is participating has not been consummated on or before the termination of the Offering Period;
provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).


 


7.2          Survival
of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers
contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement, and any Closings contemplated
hereunder.


 


7.3          Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors
and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement.


 


7.4          Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware.


 


7.5          Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any
electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.


 




    	 	A - 24	 



     


    

  


7.6          Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.


 


7.7          Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic
mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their address as set forth on the signature page or Exhibit A, or to such e-mail address, facsimile number or address as subsequently
modified by written notice given in accordance with this Section 7.7. If notice is given to the Company, a copy shall also
be sent to Sichenzia Ross Ference Kesner LLP, 1185 Avenue of the Americas, 37th Floor, New York, NY 10036, fax: 212-930-9725,
Attention: Darrin Ocasio, Esq.


 


7.8          No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission
in connection with this transaction except as described in the PPM (including, without limitation, the Company’s right to
engage a registered broker-dealer to act as Placement Agent). Each Purchaser agrees to indemnify and to hold harmless the Company
from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this
transaction (and the costs and expenses of defending against such liability or asserted liability) for which each Purchaser
or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Purchaser
from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out
of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company
or any of its officers, employees or representatives is responsible.


 


7.9          Attorneys’
Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the
Transaction Documents, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements
in addition to any other relief to which such party may be entitled.


 


7.10          Amendments
and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Company and
the holders of at least a majority of the then-outstanding shares of Series A Preferred Stock sold in the Offering, or for an amendment,
termination or waiver effected prior to the Initial Closing, Purchasers obligated to purchase a majority of the Units to be issued
at the Initial Closing. Any amendment or waiver effected in accordance with this Section 7.10 shall be binding upon the Purchasers
and each transferee of the Securities, each future holder of all such Securities, and the Company.


 




    	 	A - 25	 



     


    

  


7.11         Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.


 


7.12         Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.


 


7.13         Entire
Agreement. This Agreement (including the Exhibits hereto), and the other Transaction Documents constitute the full and entire
understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement
relating to the subject matter hereof existing between the parties are expressly canceled.


 


7.14         Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware
and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or
other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising
out of or based upon this Agreement except in the state courts of Delware or the United States District Court for the District
of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action
or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the
venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in
or by such court.


 


7.15         WAIVER
OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER
IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER
OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS,
AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS
WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS
WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION
WITH LEGAL COUNSEL. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in
the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction.


 




    	 	A - 26	 



     


    

  


7.16          No
Commitment for Additional Financing. The Company acknowledges and agrees that no Purchaser has made any representation, undertaking,
commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than
the purchase of the Units as set forth herein and subject to the conditions set forth herein. In addition, the Company acknowledges
and agrees that (i) no statements, whether written or oral, made by any Purchaser or its representatives on or after the date
of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any financing
or investment, (ii) the Company shall not rely on any such statement by any Purchaser or its representatives, and (iii) an
obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment may only be created
by a written agreement, signed by such Purchaser and the Company, setting forth the terms and conditions of such financing or investment
and stating that the parties intend for such writing to be a binding obligation or agreement. Each Purchaser shall have the right,
in its sole and absolute discretion, to refuse or decline to participate in any other financing of or investment in the Company,
and shall have no obligation to assist or cooperate with the Company in obtaining any financing, investment or other assistance.


 


7.17         Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.


 


7.18         Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in this Agreement and hereby
agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law
would be adequate.


 


7.19         Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person
or entity under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause
of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall
be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.


 




    	 	A - 27	 



     


    

  


7.20         Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. It is expressly understood and agreed that each provision
contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between
the Company and the Purchasers collectively and not between and among the Purchasers.


 


[Signature Pages Follow]


 




    	 	A - 28	 



     


    

  


IN WITNESS WHEREOF, the
parties have executed this Securities Purchase Agreement as of the date first written above.


 


	 	COMPANY:
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	Title:	 
	 	Address: 	MDNA Life Sciences, Inc.
	 	 	 
	 	 	2054 Vista Parkway
	 	 	 
	 	 	Suite 400
	 	 	 
	 	 	West Palm Beach, FL 33411
	 	 	 
	 	 	Attn: Chris Mitton, CEO


 


	 	PURCHASERS:
	 	 
	 	The Purchasers executing the Signature Page in the form attached hereto and delivering the same to the Company or its agents shall be deemed to have executed this Agreement and agreed to the terms of all Transaction Documents.


 




    	 	A - 29	 



     


    

 


PURCHASER SIGNATURE PAGE TO


 


MDNA LIFE SCIENCES, INC. SECURITIES PURCHASE
AGREEMENT


 


The undersigned, desiring to: (i) enter into
the securities purchase agreement, dated as of _____________, 2018 (the “Securities Purchase Agreement”), between
the undersigned, MDNA LIFE SCIENCES, INC., a Delaware corporation (the “Company”), and the other parties thereto,
in or substantially in the form furnished to the undersigned and purchase the units of the Company (the “Units”)
as set forth below, hereby agrees to purchase such Units from the Company and further agrees to join the Securities Purchase Agreement
as a party thereto, with all the rights and privileges appertaining thereto, and to be bound in all respects by the terms and conditions
thereof. The undersigned specifically acknowledges having read the representations section in the Securities Purchase Agreement
entitled “Representations and Warranties of the Purchasers,” and hereby represents that the statements contained therein
are complete and accurate with respect to the undersigned as a Purchaser.


 


The undersigned Purchaser hereby elects to purchase _____________________ Units ($ ___________________) under the Securities Purchase Agreement.



 


	PURCHASER (individual)	PURCHASER (entity)
	 	 
	 	 
	 	 
	Signature	Name of Entity
	 	 
	 	 
	 	 
	Print Name	Signature
	 	 
	 	Print Name:__________________________
	 	 
	Signature (if Joint Tenants or Tenants in Common)	Title:_______________________________
	 	 
	Address of Principal Residence:	Address of Executive Offices:
	 	 
	 	 
	 	 
	 	 
	 	 
	Social Security Number(s):	IRS Tax Identification Number:
	 	 
	 	 
	Telephone Number: :_______________	Telephone Number:_______________
	 	 
	Facsimile Number: :_______________	Facsimile Number: :_______________


 




    	 	A - 30	 



     


    

 


Exhibit A


 


ESCROW AGREEMENT


 


THIS ESCROW AGREEMENT (this
“Agreement”) is made as of as of the ___ day of _________________, 2018 by and among MDNA Life Sciences, Inc.,
a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (each a “Purchaser”
and together the “Purchasers”) and Sichenzia Ross Ference Kesner LLP, with an address at 1185 Avenue of the
Americas, 37th Floor, New York, New York 10036, as the escrow agent (the “Escrow Agent”).


 


WITNESSETH:


 


WHEREAS, the Company
desires to conducted a private placement offering (the “Offering”) to sell to the Purchasers units of the Company
(each unit, including the components of such unit, a “Unit,” and collectively the “Units”),
with each Unit consisting of (i) one (1) share of the Company’s Series A Convertible Preferred Stock; and (ii) a seven-year
warrant to purchase one share of the Company’s common stock, $0.001 par value per share;


 


WHEREAS, the Company
is offering each Unit at a price of $0.55 per Unit;


 


WHEREAS, the Company is
offering a minimum of $100,000 of Units (the “Minimum Offering Amount”) and, a maximum of $2,000,000 of Units;
and


 


WHEREAS, the parties
desire to establish an escrow account with the Escrow Agent into which the Purchaser shall deposit, via wire transfer or a certified
check, in immediately available funds, such Purchaser’s subscription amount as set forth on the signature page hereto (each,
a “Subscription Amount”, collectively among multiple Purchasers, the “Subscription Amounts”)
to the order of “Sichenzia Ross Ference Kesner LLP, as Escrow Agent for MDNA Life Sciences, Inc.”, and Escrow Agent
is willing to accept said deposit(s) in accordance with the terms hereinafter set forth.


 


NOW, THEREFORE,
in consideration of the covenants and mutual promises contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:


 


ARTICLE I


TERMS OF THE ESCROW


 


1.1          The
parties hereby agree to establish an escrow account (the “Escrow Account”) with the Escrow Agent whereby the
Escrow Agent shall hold the Subscription Amount deposited into the Escrow Account (the “Escrow Items”).


 


1.2          Upon
the Escrow Agent’s receipt of the Escrow Items, it shall telephonically advise the Company of said receipt into the Escrow
Account.


 




    	 	A - 31	 



     


    

 


1.3          Wire
transfers to the Escrow Agent shall be made as follows:


 


	Wire to:	Citibank	 
	 	153 East 53rd Street	 
	 	23rd Floor	 
	 	New York, NY  10022 	 
	 	 	 
	 	A/C of Sichenzia Ross Ference Kesner LLP
	 	A/C#:	4974921703
	 	ABA#:	021000089
	 	SWIFT Code:	CITIUS33


 


1.4          So
long as the aggregate Subscription Amounts received pursuant to the Offering equal or exceed the Minimum Offering Amount, the Escrow
Agent shall, upon receipt of written instructions in a form and substance satisfactory to the Escrow Agent, received from the Company,
distribute the Escrow Items in accordance with such written instructions, with any payment to be made by wire transfer within one
(1) business day of receipt of such written instructions.


 


ARTICLE II


MISCELLANEOUS


 


2.1          No
waiver or any breach of any covenant or provision herein contained shall be deemed a waiver of any preceding or succeeding breach
thereof, or of any other covenant or provision herein contained. No extension of time for performance of any obligation or act
shall be deemed an extension of the time for performance of any other obligation or act.


 


2.2          Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via
facsimile prior to 5:30 p.m. (Eastern Time) on a Business Day, (b) the next Business Day after the date of transmission, if
such notice or communication is delivered via facsimile on a day that is not a Business Day or later than 5:30 p.m. (Eastern Time)
on any Business Day, (c) the 2nd Business Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. As used herein, “Business
Day” shall mean any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized
or required by law to remain closed.


 


2.3          This
Escrow Agreement shall be binding upon and shall inure to the benefit of the permitted successors and permitted assigns of the
parties hereto.


 


2.4          This
Escrow Agreement is the final expression of, and contains the entire agreement between, the parties with respect to the subject
matter hereof and supersedes all prior understandings with respect thereto. This Escrow Agreement may not be modified, changed,
supplemented or terminated, nor may any obligations hereunder be waived, except by written instrument signed by the parties to
be charged or by its agent duly authorized in writing or as otherwise expressly permitted herein.


 




    	 	A - 32	 



     


    

  


2.5          Whenever
required by the context of this Escrow Agreement, the singular shall include the plural and masculine shall include the feminine.
This Escrow Agreement shall not be construed as if it had been prepared by one of the parties, but rather as if all parties had
prepared the same.


 


2.6          The
parties hereto expressly agree that this Escrow Agreement shall be governed by, interpreted under and construed and enforced in
accordance with the laws of the State of New York. Any action to enforce, arising out of, or relating in any way to, any provisions
of this Escrow Agreement shall only be brought in a state or Federal court sitting in New York City.


 


2.7          The
Escrow Agent’s duties hereunder may be altered, amended, modified or revoked only by a writing signed by the parties hereto.


 


2.8          The
Escrow Agent shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall
be protected in relying or refraining from acting on any instrument reasonably believed by the Escrow Agent to be genuine and to
have been signed or presented by the proper party or parties. The Escrow Agent shall not be personally liable for any act the Escrow
Agent may do or omit to do hereunder as the Escrow Agent while acting in good faith and in the absence of gross negligence, fraud
and willful misconduct.


 


2.9          The
Escrow Agent is hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other
person or corporation, excepting only orders or process of courts of law and is hereby expressly authorized to comply with and
obey orders, judgments or decrees of any court. In case the Escrow Agent obeys or complies with any such order, judgment or decree,
the Escrow Agent shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such
decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.


 


2.10          The
Escrow Agent shall not be liable in any respect on account of the identity, authorization or rights of the parties executing or
delivering or purporting to execute or deliver any documents or papers deposited or called for hereunder in the absence of gross
negligence, fraud and willful misconduct.


 


2.11          The
Escrow Agent shall be entitled to employ such legal counsel and other experts as the Escrow Agent may deem necessary properly to
advise the Escrow Agent in connection with the Escrow Agent’s duties hereunder, may rely upon the advice of such counsel,
and may pay such counsel reasonable compensation; provided that the costs of such compensation shall be borne by the Escrow Agent.


 




    	 	A - 33	 



     


    

  


2.12         The
Escrow Agent’s responsibilities as escrow agent hereunder shall terminate if the Escrow Agent shall resign by giving written
notice to the Company and Purchaser. In the event of any such resignation, the Company and Purchaser shall appoint a successor
escrow agent and the Escrow Agent shall deliver to such successor escrow agent any Escrow Items held by the Escrow Agent.


 


2.13         If
the Escrow Agent reasonably requires other or further instruments in connection with this Escrow Agreement or obligations in respect
hereto, the necessary parties hereto shall join in furnishing such instruments.


 


2.14         It
is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of
the documents (if any) or the Escrow Items held by the Escrow Agent hereunder, the Escrow Agent is authorized and directed in the
Escrow Agent’s sole discretion (i) to retain in the Escrow Agent’s possession without liability to anyone all or any
part of said documents or the Escrow Items until such disputes shall have been settled either by mutual written agreement of the
parties concerned by a final order, decree or judgment or a court of competent jurisdiction after the time for appeal has expired
and no appeal has been perfected, but the Escrow Agent shall be under no duty whatsoever to institute or defend any such proceedings
or (ii) to deliver the Escrow Items and any other property and documents held by the Escrow Agent hereunder to a state or Federal
court having competent subject matter jurisdiction and located in the City of New York in accordance with the applicable procedure
therefore.


 


2.15         The
Company and Purchaser agree jointly and severally to indemnify and hold harmless the Escrow Agent and its partners, employees,
agents and representatives from any and all claims, liabilities, costs or expenses in any way arising from or relating to the duties
or performance of the Escrow Agent hereunder or the transactions contemplated hereby other than any such claim, liability, cost
or expense to the extent the same shall have been determined by final, unappealable judgment of a court of competent jurisdiction
to have resulted from the gross negligence, fraud or willful misconduct of the Escrow Agent.


 


[Signature Page Follows]


 




    	 	A - 34	 



     


    

 


IN WITNESS WHEREOF, the parties hereto have
executed this Escrow Agreement as of date first written above.


 


	COMPANY: 	 
	MDNA Life Sciences, Inc.	 
	 	 	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	 	 
	ESCROW AGENT:	 
	SICHENZIA ROSS FERENCE KESNER LLP	 
	 	 	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 


 


 


	PURCHASER	 	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	Subscription Amount: _____________ $ ___________	 


 




    	 	A - 35	 



     


    

  


Exhibit B


 


DISCLOSURE SCHEDULE


 


This Disclosure Schedule (“Disclosure Schedule”)
is dated as of January __, 2018 and is referred to in, and is part of, that certain Securities Purchase Agreement (the “Agreement”),
dated as of the date hereof, by and among MDNA Life Sciences, Inc. (the “Company”) and the purchasers identified
on the signature page to the Agreement. Unless the context otherwise requires, all capitalized terms used in this Disclosure Schedule
shall have the respective meanings assigned to them in the Agreement.


 


This Disclosure Schedule is qualified in its entirety by reference
to specific provisions of the Agreement, and is not intended to constitute, and shall not be construed as constituting, representations
or warranties of the Company, except as and to the extent provided in the Agreement. Disclosure of any item herein shall not be
construed as an admission that (i) such item is material to the operations or financial condition of the Company or for the purposes
of the Agreement, (ii) such item could or could reasonably be expected to have a Material Adverse Effect or (iii) such item meets
any specified value threshold.


 


Matters reflected in this Disclosure Schedule are not necessarily
limited to matters required by the Agreement to be reflected in this Disclosure Schedule. Such additional matters are set forth
for informational purposes and do not necessarily include other matters of a similar nature. The representations, warranties, covenants
and other obligations and agreements of the Company in the Agreement are made, given and undertaken subject to the disclosures
in this Disclosure Schedule and as provided in the Agreement.


 


Any matter disclosed for any purpose in any Section of this Disclosure
Schedule shall be deemed to be disclosed for any other purpose in such Section or in any other Section of this Disclosure Schedule
to the extent the relevance of such matter for such other purpose is reasonably apparent on its face.


 


In the event that there is any inconsistency between the Agreement
and matters disclosed in this Disclosure Schedule, information contained in this Disclosure Schedule will prevail and will be deemed
to be the relevant disclosure.


 


The headings contained in this Disclosure Schedule are included
for convenience only, and are not intended to limit the effect of the disclosures contained in this Disclosure Schedule or to expand
the scope of the information required to be disclosed in this Disclosure Schedule.


 




    	 	A - 36	 



     


    

 


Section 2.2(c)


 


Capitalization


 


		(i)	9,497,440 shares of issued and outstanding Common Stock.



 


		(ii)	Granted stock options including vesting schedule:



 


	option holder	 	grant date	 	total grant	 	 	initial vesting 

date	 	initial vesting

 amount	 	 	balance	 	 	monthly vesting 

period	 	 	monthly vesting 

amount	 	 	vested @ 

1-Jan-18	 	 	unvested	 
	J Creed	 	17-Jan-15	 	 	200,000	 	 	17-Jan-15	 	 	66,667	 	 	 	133,333	 	 	 	24	 	 	 	5,556	 	 	 	200,000	 	 	 	0	 
	 	 	17-Jan-16	 	 	75,000	 	 	17-Jan-16	 	 	75,000	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	75,000	 	 	 	0	 
	A Harbottle	 	31-Jan-15	 	 	200,000	 	 	31-Jan-15	 	 	66,667	 	 	 	133,333	 	 	 	24	 	 	 	5,556	 	 	 	200,000	 	 	 	0	 
	 	 	1-Feb-16	 	 	75,000	 	 	1-Feb-16	 	 	75,000	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	75,000	 	 	 	0	 
	C Mitton	 	8-Jan-16	 	 	750,000	 	 	8-Jan-16	 	 	250,000	 	 	 	500,000	 	 	 	36	 	 	 	13,889	 	 	 	583,333	 	 	 	166,667	 
	Total	 	 	 	 	1,300,000	 	 	 	 	 	533,334	 	 	 	766,666	 	 	 	 	 	 	 	 	 	 	 	1,133,333	 	 	 	166,667	 





  


The option exercise price is $1.00.
The Company intends to change the exercise price of all issued options to $0.55.


 


		(iii)	2,200,000 shares of Common Stock have been reserved under the RSU Plan. Below is a table reflecting
the RSU vesting schedule:



 


	RSU	 	RSUs granted	 	grant	 	total	 	 	vested @	 	 	vest 1 year	 
	holder	 	in relation to......	 	date	 	grant	 	 	1-Jan-18	 	 	from grant	 
	J Creed	 	Employment contract	 	31-Jan-15	 	 	40,000	 	 	 	40,000	 	 	 	 	 
	A Harbottle	 	Employment contract	 	31-Jan-14	 	 	20,000	 	 	 	20,000	 	 	 	 	 
	H Smart	 	Director remuneration 14/15	 	3-Nov-14	 	 	100,000	 	 	 	100,000	 	 	 	 	 
	R Boxer	 	Director remuneration 14/15	 	11-Nov-14	 	 	50,000	 	 	 	50,000	 	 	 	 	 
	R Thayer	 	Director remuneration 14/15	 	19-Nov-14	 	 	50,000	 	 	 	50,000	 	 	 	 	 
	CAM	 	Bridge Loan	 	29-Nov-14	 	 	10,000	 	 	 	10,000	 	 	 	 	 
	H Smart	 	Director remuneration 15/16	 	3-Nov-15	 	 	200,000	 	 	 	200,000	 	 	 	 	 
	C Hill	 	Director remuneration 15/16	 	11-Nov-15	 	 	50,000	 	 	 	50,000	 	 	 	 	 
	R Boxer	 	Director remuneration 15/16	 	11-Nov-15	 	 	50,000	 	 	 	50,000	 	 	 	 	 
	R Thayer	 	Director remuneration 15/16	 	19-Nov-15	 	 	50,000	 	 	 	50,000	 	 	 	 	 
	H Smart	 	Bridge Loan - September 2015	 	5-Mar-16	 	 	139,931	 	 	 	139,931	 	 	 	 	 
	T Ward	 	Bridge Loan - September 2015	 	5-Mar-16	 	 	64,583	 	 	 	64,583	 	 	 	 	 
	H Smart	 	Bridge Loan - October 2015	 	12-Apr-16	 	 	139,931	 	 	 	139,931	 	 	 	 	 
	R Boxer	 	Bridge Loan - November 2015	 	12-May-16	 	 	28,750	 	 	 	28,750	 	 	 	 	 
	H Smart	 	Bridge Loan - December 2015	 	17-Jun-16	 	 	118,403	 	 	 	118,403	 	 	 	 	 
	H Smart	 	Bridge Loan - January 2016	 	26-Jul-16	 	 	230,506	 	 	 	230,506	 	 	 	 	 
	H Smart	 	Bridge Loan - March 2016	 	9-Sep-16	 	 	156,253	 	 	 	156,253	 	 	 	 	 
	T de Ris	 	Bridge Loan - April 2016	 	4-Oct-16	 	 	43,061	 	 	 	43,061	 	 	 	 	 
	H Smart	 	Bridge Loan - May 2016	 	3-Nov-16	 	 	215,278	 	 	 	215,278	 	 	 	 	 
	T Ward	 	Bridge Loan - May 2016	 	10-Nov-16	 	 	21,528	 	 	 	21,528	 	 	 	 	 
	H Smart	 	Director remuneration 16/17	 	3-Nov-16	 	 	250,000	 	 	 	250,000	 	 	 	 	 
	C Hill	 	Director remuneration 16/17	 	11-Nov-16	 	 	75,000	 	 	 	75,000	 	 	 	 	 
	R Boxer	 	Director remuneration 16/17	 	11-Nov-16	 	 	75,000	 	 	 	75,000	 	 	 	 	 
	R Thayer	 	Director remuneration 16/17	 	19-Nov-16	 	 	75,000	 	 	 	75,000	 	 	 	 	 
	R Boxer	 	Bridge Loan - June 2016	 	2-Dec-16	 	 	25,000	 	 	 	25,000	 	 	 	 	 
	H Smart	 	Bridge Loan - July 2016	 	4-Jan-17	 	 	215,278	 	 	 	215,278	 	 	 	 	 
	R Boxer	 	Bridge Loan - August 2016	 	2-Feb-17	 	 	25,000	 	 	 	25,000	 	 	 	 	 
	H Smart	 	Bridge Loan - August 2016	 	12-Feb-17	 	 	182,986	 	 	 	182,986	 	 	 	 	 
	H Smart	 	Bridge Loan - September 2016	 	16-Mar-17	 	 	203,353	 	 	 	203,353	 	 	 	 	 
	P Forte	 	in lieu of cash remuneration	 	1-Oct-17	 	 	100,000	 	 	 	100,000	 	 	 	 	 
	H Smart	 	Director remuneration 17/18	 	3-Nov-17	 	 	250,000	 	 	 	0	 	 	 	250,000	 
	C Hill	 	Director remuneration 17/18	 	11-Nov-17	 	 	75,000	 	 	 	0	 	 	 	75,000	 
	R Boxer	 	Director remuneration 17/18	 	11-Nov-17	 	 	75,000	 	 	 	0	 	 	 	75,000	 
	R Thayer	 	Director remuneration 17/18	 	19-Nov-17	 	 	75,000	 	 	 	0	 	 	 	75,000	 
	Total	 	 	 	 	 	 	3,479,841	 	 	 	3,004,841	 	 	 	475,000	 



 




    	 	A - 37	 



     


    

  


Please see table below for further information


 


Capitalization Table, as of the date of this Memorandum


 


	Stock Issued	 	 	 	 
	Common shares	 	 	9,497,440	 
	Restricted share units	 	 	3,004,841	 
	Series A shares	 	 	4,294,445	 
	Total stock issued	 	 	16,796,726	 
	 	 	 	 	 
	Common Stock potentially to be issued upon conversion or exercise of:	 	 	 	 
	Restricted share units - unvested	 	 	475,000	 
	5-year secured loan conversions	 	 	11,822,735	 
	Series A shares from short term secured loan conversions	 	 	5,124,335	 
	Options – vested	 	 	1,133,333	 
	Options – unvested	 	 	166,667	 
	General warrants	 	 	7,835,908	 
	Series A warrants	 	 	4,321,692	 
	Potential warrants from short term secured loan conversions	 	 	5,124,335	 
	Total potential common stock	 	 	36,004,006	 
	 	 	 	 	 
	Total Issued and Potential Common Stock	 	 	52,800,732	 



 




    	 	A - 38	 



     


    

  


Section 2.2(d)


 


Acceleration Provisions


 


The Company’s 2015 Stock Option and Incentive Plan provides
that the Board of Directors may at any time provide that any of the Company’s options shall become immediately exercisable
in full or in part, and that any restricted stock awards shall be free of some or all restrictions, or that any other stock based
awards may become exercisable in full or in part.


 




    	 	A - 39	 



     


    

 


Section 2.7


 


Litigation


 


The Company may be exposed to litigation with
Dr. Steinfels. Dr. Steinfels previously served as President and CEO of the Company and is a former member of the Board of Directors.
In March 2016 an attorney representing Dr. Steinfels notified the Company that he is seeking compensation relating to his tenure
as President and CEO. The amount of payment demanded is not considered material to Company operations and is being vigorously disputed
by the Company, as the Company does not believe it owes any money to this former employee.


 




    	 	A - 40	 



     


    

 







Section 2.8


 


Intellectual Property


 







	Country	 	Title	 	
        Application 

        No.
	 	Filing 

Date	 	Patent No.	 	Issue 

Date	 	Status	 	Applicant/ 

Assignee
	AT	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	E 484589	 	Oct 13/2010	 	I	 	Mitomics Inc.
	AU	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	2009227935	 	Mar 27/2009	 	2009227935	 	Oct 22/2015	 	I	 	MDNA Life Sciences Inc.
	AU	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	2010234238	 	Mar 29/2010	 	 	 	 	 	AL	 	MDNA Life Sciences Inc.
	AU	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	2008310257	 	Oct 14/2008	 	2008310257	 	Mar 20/2014	 	I	 	MDNA Life Sciences Inc.



 



    	 	A - 41	 



     


    

  


	AU	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	2008324675	 	Nov 10/2008	 	2008324675	 	Aug 06/2015	 	I	 	MDNA Life Sciences Inc.
	AU	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	2006238390	 	Apr 18/2006	 	2006238390	 	Nov 10/2011	 	I	 	Mitomics Inc.
	AU	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	2011242123	 	Apr 18/2006	 	2011242123	 	Dec 24/2013	 	I	 	Mitomics Inc.
	AU	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	2011223463	 	Mar 01/2011	 	2011223463	 	Nov 12/2015	 	I	 	MDNA Life Sciences Inc.
	BE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	BE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.



 






    	 	A - 42	 



     


    

  


	BE	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	BE	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	CA	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	2,700,941	 	Sep 26/2007	 	 	 	 	 	P	 	Mitomics Inc.
	CA	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	2,719,718	 	Mar 27/2009	 	 	 	 	 	AB	 	Mitomics Inc.
	CA	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	2,756,824	 	Mar 29/2010	 	 	 	 	 	AB	 	Mitomics Inc.



 






    	 	A - 43	 



     


    

  


	CA	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	2,702,212	 	Oct 14/2008	 	 	 	 	 	P	 	Mitomics Inc.
	CA	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	2,704,361	 	Nov 10/2008	 	 	 	 	 	P	 	Mitomics Inc.
	CA	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer and Other Cancers	 	2,792,443	 	Apr 18/2006	 	 	 	 	 	AB	 	Mitomics Inc.
	CA	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer and Other Cancers	 	2,606,156	 	Apr 18/2006	 	2,606,156	 	Jan 08/2013	 	I	 	Mitomics Inc.
	CA	 	The Use of a 3895 bp Mitochondrial DNA Deletion as a Marker for Sunlight Exposure in Human Skin	 	2,480,184	 	Oct 14/2004	 	2,480,184	 	Dec 20/2011	 	I	 	Mitomics Inc.



 






    	 	A - 44	 



     


    

  


	CA	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	2,791,817	 	Mar 01/2011	 	 	 	 	 	AB	 	Mitomics Inc.
	CH	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	CN	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	200780101671.5	 	Sep 26/2007	 	200780101671.5	 	Jan 28/2015	 	I	 	Mitomics Inc.
	CN	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	200980114773.X	 	Mar 27/2009	 	 	 	 	 	P	 	Mitomics Inc.
	CN	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	201080014122.6	 	Mar 29/2010	 	201080014122.6	 	Jul 08/2015	 	I	 	Mitomics Inc.



 






    	 	A - 45	 



     


    

  


	CN	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	200880119849.3	 	Oct 14/2008	 	200880119849.3	 	Jul 22/2015	 	I	 	Mitomics Inc.
	CN	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	200880115243.2	 	Nov 10/2008	 	200880115243.2	 	Feb 12/2014	 	I	 	Mitomics Inc.
	CN	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	200680021903.1	 	Apr 18/2006	 	ZL2006800219031	 	Sep 25/2013	 	I	 	Mitomics Inc.
	CN	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	201310399746.X	 	Apr 18/2006	 	 	 	 	 	P	 	Mitomics Inc.
	CN	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	201180011806.5	 	Mar 01/2011	 	201180011806.5	 	Jun 17/2015	 	I	 	Mitomics Inc.



 






    	 	A - 46	 



     


    

  


	CN	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	201510253175.8	 	Mar 01/2011	 	 	 	 	 	P	 	Mitomics Inc.
	CZ	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	DE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	602007036277.6	 	Apr 23/2014	 	I	 	Mitomics Inc.
	DE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	602007040305.7	 	Feb 18/2015	 	I	 	Mitomics Inc.
	DE	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	602008034010.4	 	Aug 20/2014	 	I	 	Mitomics Inc.
	DE	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	602006017534.5	 	Oct 13/2010	 	I	 	Mitomics Inc.



 






    	 	A - 47	 



     


    

  


	DK	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	EP	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	09725638.2	 	Mar 27/2009	 	 	 	 	 	AL	 	MDNA Life Sciences Inc.
	EP	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	10761136.0	 	Mar 29/2010	 	 	 	 	 	P	 	MDNA Life Sciences Inc.
	EP	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	08846547.1	 	Nov 10/2008	 	 	 	 	 	P	 	MDNA Life Sciences Inc.



 






    	 	A - 48	 



     


    

  


	EP	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	10013553.2	 	Apr 18/2006	 	 	 	 	 	AL	 	MDNA Life Sciences Inc.
	EP	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	11750131.2	 	Mar 01/2011	 	 	 	 	 	P	 	MDNA Life Sciences Inc.
	ES	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	ES 2484044 T3	 	Apr 23/2014	 	I	 	Mitomics Inc.
	ES	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	ES	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	ES	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.



 






    	 	A - 49	 



     


    

  


	FI	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	FI	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	FI	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	FI	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	FR	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	FR	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	FR	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.



 






    	 	A - 50	 



     


    

 


	FR	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	GB	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	GB	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	GB	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	GB	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	GR	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.



 






    	 	A - 51	 



     


    

  


	HK	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	10111822.9	 	Sep 26/2007	 	1145343	 	Feb 13/2015	 	I	 	Mitomics Inc.
	HK	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	11107129.6	 	Mar 27/2009	 	 	 	 	 	P	 	Mitomics Inc.
	HK	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	12107393.4	 	Mar 29/2010	 	 	 	 	 	P	 	Mitomics Inc.
	HK	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	10111821.0	 	Oct 14/2008	 	 	 	 	 	AL	 	Mitomics Inc.
	HK	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	10111820.1	 	Nov 10/2008	 	 	 	 	 	P	 	Mitomics Inc.



 






    	 	A - 52	 



     


    

  


	HK	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool for The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	11113767.1	 	Apr 18/2006	 	 	 	 	 	P	 	Mitomics Inc.
	HK	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	13107822.4	 	Mar 01/2011	 	 	 	 	 	P	 	Mitomics Inc.
	HU	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	IE	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	IN	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	2680/DELNP/2010	 	Sep 26/2007	 	 	 	 	 	P	 	Mitomics Inc.



 



    	 	A - 53	 



     


    

 


	IN	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	6645/CHENP/2010	 	Mar 27/2009	 	 	 	 	 	P	 	Mitomics Inc.
	IN	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	6821/DELNP/2011	 	Mar 29/2010	 	 	 	 	 	P	 	Mitomics Inc.
	IN	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	2490/DELNP/2010	 	Oct 14/2008	 	 	 	 	 	P	 	Mitomics Inc.
	IN	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use In The Detection of Cancer	 	2658/DELNP/2010	 	Nov 10/2008	 	 	 	 	 	P	 	Mitomics Inc.
	IN	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	8896/DELNP/2007	 	Apr 18/2006	 	 	 	 	 	P	 	Mitomics Inc.



 






    	 	A - 54	 



     


    

 


	IN	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	7267/DELNP/2012	 	Mar 01/2011	 	 	 	 	 	P	 	Mitomics Inc.
	IT	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	IT	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	IT	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	IT	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	JP	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	2010-526114	 	Sep 26/2007	 	5518715	 	Apr 11/2014	 	I	 	Mitomics Inc.



 






    	 	A - 55	 



     


    

  


	JP	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	2011-501069	 	Mar 27/2009	 	5938690	 	May 27/2016	 	I	 	MDNA Life Sciences Inc.
	JP	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	2012-501093	 	Mar 29/2010	 	5734947	 	Apr 24/2015	 	I	 	MDNA Life Sciences Inc.
	JP	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	2010-528251	 	Oct 14/2008	 	5646998	 	Nov 14/2014	 	I	 	MDNA Life Sciences Inc.
	JP	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	2010-532390	 	Nov 10/2008	 	5481383	 	Feb 21/2014	 	I	 	MDNA Life Sciences Inc.
	JP	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	2008-505707	 	Apr 18/2006	 	5537804	 	May 09/2014	 	I	 	Mitomics Inc.



 






    	 	A - 56	 



     


    

 


	JP	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	2012-101409	 	Apr 18/2006	 	 	 	 	 	P	 	Mitomics Inc.
	JP	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	2012-555266	 	Mar 01/2011	 	6008743	 	Sep 23/2016	 	I	 	MDNA Life Sciences Inc.
	KR	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	10-2010-7007603	 	Sep 26/2007	 	10-1449562	 	Oct 02/2014	 	I	 	Mitomics Inc.
	KR	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	10-2010-7024109	 	Mar 27/2009	 	 	 	 	 	AL	 	MDNA Life Sciences Inc.
	KR	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	 	 	 	 	 	 	 	 	P	 	MDNA Life Sciences Inc.



 



    	 	A - 57	 



     


    

 


	KR	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	10-2011-7025261	 	Mar 29/2010	 	 	 	 	 	P	 	Mitomics Inc.
	KR	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	2010-7010235	 	Oct 14/2008	 	 	 	 	 	P	 	MDNA Life Sciences Inc.
	KR	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	2010-7012456	 	Nov 10/2008	 	10-1644661	 	Jul 26/2016	 	I	 	MDNA Life Sciences Inc.
	KR	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	10-2007-7026442	 	Apr 18/2006	 	10-1363032	 	Feb 07/2014	 	I	 	Mitomics Inc.
	KR	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	10-2012-7022982	 	Mar 01/2011	 	 	 	 	 	P	 	MDNA Life Sciences Inc.



 






    	 	A - 58	 



     


    

  


	LI	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	MO	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	J/001286 (273)	 	Apr 18/2006	 	ZL2006800219031	 	Apr 18/2014	 	I	 	Mitomics Inc.
	NL	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	NL	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	NL	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	NL	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.



 






    	 	A - 59	 



     


    

  


	NZ	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	584815	 	Sep 26/2007	 	584815	 	Nov 05/2012	 	I	 	Mitomics Inc.
	NZ	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	588658	 	Mar 27/2009	 	588658	 	Jan 29/2013	 	I	 	Mitomics Inc.
	NZ	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	602175	 	Mar 27/2009	 	602175	 	Jul 01/2014	 	I	 	Mitomics Inc.
	NZ	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	595114	 	Mar 29/2010	 	595114	 	Mar 29/2014	 	I	 	Mitomics Inc.
	NZ	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	584595	 	Oct 14/2008	 	584595	 	Oct 14/2012	 	I	 	Mitomics Inc.



 






    	 	A - 60	 



     


    

  


	NZ	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	584656	 	Nov 10/2008	 	584656	 	Dec 11/2012	 	I	 	Mitomics Inc.
	NZ	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	562928	 	Apr 18/2006	 	562928	 	May 09/2011	 	I	 	Mitomics Inc.
	NZ	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	587665	 	Apr 18/2006	 	587665	 	Mar 05/2012	 	I	 	Mitomics Inc.
	NZ	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	602137	 	Mar 01/2011	 	602137	 	Sep 01/2015	 	I	 	Mitomics Inc.
	PT	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.



 






    	 	A - 61	 



     


    

  


	SE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	07815900.1	 	Sep 26/2007	 	2203570	 	Apr 23/2014	 	I	 	Mitomics Inc.
	SE	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	13169334.3	 	Sep 26/2007	 	2634267	 	Feb 18/2015	 	I	 	Mitomics Inc.
	SE	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	08838509.1	 	Oct 14/2008	 	2217730	 	Aug 20/2014	 	I	 	Mitomics Inc.
	SE	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	06741413.6	 	Apr 18/2006	 	1877559	 	Oct 13/2010	 	I	 	Mitomics Inc.
	SG	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	10201600490P	 	Sep 26/2007	 	 	 	 	 	P	 	Mitomics Inc.
	SG	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	201007002-7	 	Mar 27/2009	 	165007	 	Nov 29/2013	 	I	 	Mitomics Inc.



 






    	 	A - 62	 



     


    

  


	SG	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	201305044-8	 	Mar 27/2009	 	 	 	 	 	P	 	Mitomics Inc.
	SG	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	10201400985R	 	Mar 29/2010	 	 	 	 	 	P	 	Mitomics Inc.
	SG	 	Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples	 	201002286-1	 	Oct 14/2008	 	160156	 	Sep 14/2012	 	I	 	Mitomics Inc.
	SG	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	201002643-3	 	Nov 10/2008	 	160787	 	Jun 30/2011	 	I	 	Mitomics Inc.
	SG	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	200716944-4	 	Apr 18/2006	 	138638	 	Nov 30/2010	 	I	 	Mitomics Inc.



 






    	 	A - 63	 



     


    

  


	SG	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	2014011837	 	Apr 18/2006	 	 	 	 	 	P	 	Mitomics Inc.
	SG	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	10201501541Q	 	Mar 01/2011	 	 	 	 	 	P	 	Mitomics Inc.
	US	 	3.4 KB Mitochondrial DNA Deletion for Use in The Detection of Cancer	 	14/874,155	 	Oct 02/2015	 	 	 	 	 	P	 	Mitomics Inc.
	US	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Hybridization Probes Therefor	 	14/627,755	 	Feb 20/2015	 	 	 	 	 	P	 	MDNA Life Sciences Inc.
	US	 	Aberrant Mitochondrial DNA, Associated Fusion Transcripts and Translation Products and Hybridization Probes Therefor	 	13/260,497	 	Mar 29/2010	 	8,715,960	 	May 06/2014	 	I	 	Mitomics Inc.



 






    	 	A - 64	 



     


    

  


	US	 	Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in The Detection of Cancer	 	15/188,604	 	Jun 21/2016	 	 	 	 	 	P	 	Mitomics Inc.
	US	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	11/975,390	 	Apr 18/2006	 	8,008,008	 	Aug 30/2011	 	I	 	Mitomics Inc.
	US	 	Mitochondrial Mutations and Rearrangements as a Diagnostic Tool For The Detection of Sun Exposure, Prostate Cancer, and Other Cancers	 	14/470,627	 	Aug 27/2014	 	 	 	 	 	P	 	Mitomics Inc.
	US	 	UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof	 	14/569,147	 	Dec 12/2014	 	 	 	 	 	P	 	Mitomics Inc.




 





Trademarks


 


	
         

        1241572
	 	
        PseudoFree –

        Registered Nov 4 2005 Reg #TMA652,270

        Owned by Mitomics Inc.
	CA







 



    	 	A - 65	 



     


    

  


Section 2.10(a)(i)


 


Agreements


 


		1.	Non-Exclusive License Agreement, dated March 1, 2016, between the Company and Phi Life Sciences,
LLC.



 


		2.	Master Services Agreement, dated March 15, 2013, among Mitomics (USA) Inc. and Clinical Reference
Laboratory, Inc.; Statement of Work Order thereunder, dated July 12, 2016, between the Company and Clinical Reference Laboratory,
Inc.



 


		3.	Exclusive License Agreement, dated December 22, 2017, between the Company and Laboratory Corporation
of America Holdings.



 




    	 	A - 66	 



     


    

  


Section 2.10(a)(ii)/(iii)


 


Agreements


 


		1.	Non-Exclusive License Agreement, dated March 1, 2016, between the Company and Phi Life Sciences,
LLC.



 


		2.	Collaboration Agreement, dated November 14, 2014, between Cambridge University Hospitals NHS Foundation
Trust and Mitomics UK.



 


		3.	Master Services Agreement, dated March 15, 2013, among Mitomics (USA) Inc. and Clinical Reference
Laboratory, Inc.; Statement of Work Order thereunder, dated July 12, 2016, between the Company and Clinical Reference Laboratory,
Inc.



 


		4.	Amended and Restated Non-Exclusive License Agreement, dated December 10, 2011 between Mitomics
Inc. and QDx Pathology Services, Inc.



 


		5.	Exclusive License Agreement, dated December 22, 2017, between the Company and Laboratory Corporation
of America Holdings.



  



    	 	A - 67	 



     


    

 


Section 2.10(b)


 


Agreements/Indebtedness


 


Summary of Secured Short Term Notes:


 


	 	 	 	 	 	 	 	 	 	 	 	 	Interest due as at	 	 	Balance as at	 
		 	 	 	 	 	Principal	 	 	1-Jan-18	 
	Lender	 	Note type	 	Issue date	 	original currency	 	 	USD equivalent	 	 	original currency	 	 	original currency	 	 	USD equivalent	 
	S Schalk (Dawson James)	 	90-day	 	24-Mar-15	 	$	25,000.00	 	 	$	25,000.00	 	 	$	14,741.78	 	 	$	39,741.78	 	 	$	39,741.78	 
	R Keyser (Dawson James)	 	90-day	 	27-Mar-15	 	$	25,000.00	 	 	$	25,000.00	 	 	$	14,704.79	 	 	$	39,704.79	 	 	$	39,704.79	 
	S Schalk (Dawson James)	 	90-day	 	1-Jun-15	 	$	50,000.00	 	 	$	50,000.00	 	 	$	27,782.19	 	 	$	77,782.19	 	 	$	77,782.19	 
	C Mitton	 	12 month restructured	 	30-Sep-17	 	$	57,966.17	 	 	$	57,966.17	 	 	$	1,476.95	 	 	$	59,443.12	 	 	$	59,443.12	 
	H Smart £UK	 	12 month restructured	 	30-Sep-17	 	£	1,424,570.62	 	 	£	1,908,924.64	 	 	£	36,297.28	 	 	£	1,460,867.90	 	 	£	1,951,719.52	 
	Panda Bay (Harvey Cardwell)	 	12 month restructured	 	30-Sep-17	 	$	65,088.20	 	 	$	52,200.73	 	 	$	1,658.41	 	 	$	66,746.61	 	 	$	51,928.86	 
	R Boxer	 	12 month restructured	 	30-Sep-17	 	$	95,903.18	 	 	$	95,903.18	 	 	$	2,443.56	 	 	$	98,346.74	 	 	$	98,346.74	 
	R Poulter $CAD	 	12 month restructured	 	30-Sep-17	 	$	24,135.75	 	 	$	19,356.87	 	 	$	614.97	 	 	$	24,750.72	 	 	$	19,256.06	 
	R Poulter $USD	 	12 month restructured	 	30-Sep-17	 	$	180,232.88	 	 	$	180,232.88	 	 	$	4,592.23	 	 	$	184,825.11	 	 	$	184,825.11	 
	T de Ris £UK	 	12 month restructured	 	30-Sep-17	 	£	25,973.41	 	 	£	34,804.37	 	 	£	661.79	 	 	£	26,635.20	 	 	£	35,584.63	 
	T Ward £UK	 	12 month restructured	 	30-Sep-17	 	£	55,283.71	 	 	£	74,080.18	 	 	£	1,408.60	 	 	£	56,692.31	 	 	£	75,740.93	 
	W Poulter $ CAD	 	12 month restructured	 	30-Sep-17	 	$	205,845.40	 	 	$	165,088.01	 	 	$	5,244.83	 	 	$	211,090.23	 	 	$	164,228.20	 
	H Smart £UK	 	12 month restructured	 	30-Aug-17	 	£	200,000.00	 	 	£	268,000.00	 	 	£	6,794.52	 	 	£	206,794.52	 	 	£	276,277.48	 
	J Creed	 	New 12 month	 	31-Aug-17	 	$	99,996.00	 	 	$	99,996.00	 	 	$	3,369.73	 	 	$	103,365.73	 	 	$	103,365.73	 
	R Poulter	 	New 12 month	 	31-Aug-17	 	$	115,000.00	 	 	$	115,000.00	 	 	$	3,875.34	 	 	$	118,875.34	 	 	$	118,875.34	 
	J Riccardi	 	New 12 month	 	30-Sep-17	 	$	99,113.00	 	 	$	99,113.00	 	 	$	2,525.34	 	 	$	101,638.34	 	 	$	101,638.34	 
	H Smart £UK	 	New 12 month	 	23-Oct-17	 	£	100,000.00	 	 	£	131,900.00	 	 	£	1,917.81	 	 	£	101,917.81	 	 	£	136,162.19	 
	C Hill	 	New 12 month	 	23-Oct-17	 	£	5,000.00	 	 	£	6,595.00	 	 	£	95.89	 	 	£	5,095.89	 	 	£	6,808.11	 
	R Poulter	 	New 12 month	 	31-Oct-17	 	$	115,173.00	 	 	$	115,173.00	 	 	$	1,956.36	 	 	$	117,129.36	 	 	$	117,129.36	 
	H Smart £UK	 	New 12 month	 	22-Nov-17	 	$	175,000.00	 	 	$	232,225.00	 	 	$	1,917.81	 	 	$	176,917.81	 	 	$	236,362.19	 
	H Smart £UK	 	New 12 month	 	27-Dec-17	 	$	150,000.00	 	 	$	200,400.00	 	 	$	205.48	 	 	$	150,205.48	 	 	$	200,674.52	 
	 	 	 	 	 	 	 	 	 	 	$	3,956,959.03	 	 	 	 	 	 	 	 	 	 	$	4,095,595.20	 





 


Long Term Note Summary:


 


	
Long Term
 Note Type
	 	Conversion Ratio	 	 	Total Principal	 	 	Number of
 Common Shares
 Post-Conversion
	 
	#1	 	 	1.66	 	 	$	6,108,870.39	 	 	 	10,140,725	 
	#2	 	 	2.16	 	 	$	70,745.00	 	 	 	152,809	 
	#3	 	 	2.19	 	 	$	436,970.19	 	 	 	956,965	 
	#4	 	 	1.91	 	 	$	299,600.00	 	 	 	572,236	 
	 	 	 	 	 	 	$	6,916,185.58	 	 	 	11,822,735	 



 


The interest on the Company’s long term notes is due from
November 17, 2016 at 8% per annum payable annually in arrears.


 




    	 	A - 68	 



     


    

  


Section 2.11(b)


 


Certain Transactions


 


To the extent applicable, see Disclosure 2.10(b) above.


 




    	 	A - 69	 



     


    

  


Section 2.13


 


Property


 


As disclosed in Disclosure 2.10(b) the Company maintains certain
secured short term notes. Such note-holders, as a result of filing UCC Financing Statements, maintain security interests in certain
assets of the Company. The Company also granted a priority security interest over its present and after-acquired personal property
to the holders of the long term notes.


 




    	 	A - 70	 



     


    

  


Section 2.15


 


Changes


 


(e)


 


		·	The Company has entered into Note Extension Agreements with certain short-term note holders to extend the maturity date, reduce
the interest rate, and receive one warrant for every $5 dollars owed in exchange for waiver of any default thereunder.



 


(g) As disclosed in the PPM and herein in Sections 2.10(b) and 2.13,
the Company has granted secured short-term note holders a security interest in certain assets of the Company. The Company also
granted a priority security interest over its present and after-acquired personal property to the holders of the long term notes.


 


(i) The Company cancelled, terminated and declared null and void
the securities issued pursuant to the 2015 Offering.


 


(l) The Company is in technical default with regard to two of its
short-term note holders. The Company owes approximately $157,228 to such note holders.


 




    	 	A - 71	 



     


    

  


Section 2.16(b)


 


Employee Matters


 


	Jack Riccardi	 	Previous CFO	 	$	114,113	 
	 	 	 	 	 	 	 
	Andrea Maggrah	 	Lab Operations Manager	 	$	11,250	 
	 	 	 	 	 	 	 
	 	 	Total	 	$	548,525	 



 




    	 	A - 72	 



     


    

  


Section 2.16(c)


 


Severance


 


	Employee	 	Title	 	Annual Salary	 	 	Severence
	Chris Mitton	 	CEO	 	$	200,000	 	 	6 months
	Jennifer Ceeed	 	CDO	 	$	180,000	 	 	6 months
	Andrew Harbottle	 	CSO	 	$	110,000	 	 	13.5 Weeks
	Andrea Maggrah	 	Lab Operations Mgr	 	$	60,000	 	 	28 Weeks



 




    	 	A - 73	 



     


    

  


Section 2.16(e)


 


Employment/Consulting Agreements


 


	Employee	 	Title	 	Annual Compensation	 
	Chris Mitton	 	CEO	 	$	200,000	 
	Jennifer Ceeed	 	CDO	 	$	180,000	 
	Andrew Harbottle	 	CSO	 	$	110,000	 
	Andrea Maggrah	 	Lab Operations Manager	 	$	60,000	 
	Robert Poulter	 	Business Development Consultant	 	$	180,000	 
	Philip Forte	 	CFO	 	$	220,000	 



 




    	 	A - 74	 



     


    

  


Section 2.17


 


Taxes


 


The Company has not filed tax returns for the fiscal years ending
September 30, 2015, September 30, 2016, and September 30, 2017. Harless and Associates in West Palm Beach, Florida, has been engaged
to prepare such returns.


 




    	 	A - 75	 



     


    

 


EXHIBIT B


 


Accredited
Investor Questionnaire


 


Dear Investor:


 


The information contained
in this questionnaire is being furnished to MDNA Life Sciences, Inc., a Delaware corporation (the “Company”),
in order that the Company may determine whether acquisition of the Company’s securities (the “Securities”)
may be made by you, as an investor, in light of the requirements of Regulation D promulgated under the Securities Act of 1933,
as amended (the “Securities Act”), and certain exemptions contained in state securities laws. You understand
that the information is needed for the Company to determine whether it has reasonable grounds to believe that you are an “accredited
investor” as that term is defined in Regulation D and that you have such knowledge and experience in financial, investment
and business matters and that you are capable of evaluating the merits and risks of the proposed investment in the Securities.
You understand that (a) the Company will rely on the information contained herein for purposes of such determination, (b) the Securities
may not be registered under the Securities Act, (c) the Securities may not be registered under the securities laws of any state,
and (d) this questionnaire is not an offer to acquire the Securities or any other securities in any case where such offer would
not be legally permitted.


 


Information contained in
this questionnaire will be kept confidential by the Company and its agents, employees and representatives. You understand, however,
that the Company may have the need to present it to such parties as it deems advisable in order to establish the applicability
under any federal or state securities laws of an exemption from registration.


 


In accordance with the
foregoing, the following representations and information are hereby made and furnished by the investor:


 


Please answer all questions.
If the answer is “none” or “not applicable,” please so state.


 


INFORMATION REQUIRED OF EACH PROSPECTIVE INVESTOR:


 


	1.	A.	If Investor is an Individual:


 


	Name:	 	 	Age:	 
	Social Security Number:	 	 	No. of Dependents:	 
	Marital Status:	 	 	Citizenship:	 
	 	 	 	 	 
	If interests are to be jointly held:	 
	 	 	 	 	 
	Name:	 	 	Age:	 
	Social Security Number:	 	 	No. of Dependents:	 
	Marital Status:	 	 	Citizenship:	 


 


		B.	If Investor is an Entity:



 


	Name	 	 	State of Organization:	 
	EIN:	 	 	Date of Formation:	 


 




    	 	B - 1	 



     


    

 


	2.	A.	If Investor is an Individual:


 


	Residence Address:	 
	 	 
	Mailing Address (if different):	 
	 	 


 


Telephone Number: _______________________________


Facsimile Number: ________________________________


Email Address: ___________________________________


 


		B.	If Investor is an Entity:



 


	Business Address:	 
	 	 
	Mailing Address (if different):	 
	 	 


 


Telephone Number: _______________________________


Facsimile Number: ________________________________


Email Address: ___________________________________


 


	3.	A.	If
Investor is an Individual:



 


State in which the investor:


is licensed to drive: _______________

is registered to vote: ______________


 


		B.	If Investor is an Entity:



 


State in which the investor:


files income tax returns: ___________________

has principal place of business: ______________


 


		4.	If Investor is an Individual:



 


	Please describe your current employment, including the name of the business and any entity by which you are employed and its principal business:
	 	 
	 	 
	Please describe any college or graduate degrees held by you:  	 
	 	 
	 	 


 




    	 	B - 2	 



     


    

 


		5.	If Investor is an Entity:



 


Provide the total assets of the entity
as of a recent date:*


 


Assets:  $_________________ Date:  ___________________



 


* In the event the entity has
less than $5,000,000 in assets, each shareholder, partner, member, or beneficiary (in the case of a trust), as applicable, must
be an accredited investor and complete this questionnaire.


 


		6.	If Investor is an Individual:



 


Please initial on the line applicable
to you under “Individual” and to you and your spouse under “Joint”:


 


		(a)	Gross Income During Last Two Years



 


	Individual	Joint (with spouse)	 
	2016	2015	2016	2015	 
	_______	_______	_______	_______	Less than $200,000
	_______	_______	_______	_______	$200,000 - 299,000
	_______	_______	_______	_______	$300,000 - 1,000,000
	_______	_______	_______	_______	More than $1,000,000


 


		(b)	Anticipated Gross Income During 2017



 


	Individual	Joint (with spouse)	 
	_______	_______	Less than $200,000
	_______	_______	$200,000 - 299,000
	_______	_______	$300,000 - 1,000,000
	_______	_______	More than $1,000,000


 


		(c)	Current “Net
                                         Worth” (Exclusive of Primary Residence)1



 


	_______	Less than $1,000,000
	_______	$1,000,000 - $5,000,000
	_______	More than $5,000,000


 





 






1 “Net Worth” means
the excess of total assets at fair market value, including cash, stock, securities, personal property and real estate (other
than your primary residence), over total liabilities (other than a mortgage or other debt secured by your
primary residence). In the event that the amount of any mortgage or other indebtedness secured by your primary residence exceeds
the fair market value of the residence, that excess liability must also be deducted from your net worth. Any mortgage or indebtedness
secured by your primary residence incurred within 60 days before the time of the sale of the securities offered hereunder, other
than as a result of the acquisition of the primary residence, shall also be deducted from your net worth.


 



    	 	B - 3	 



     


    

 


		7.	Is the investor involved in any litigation, which, if an adverse decision occurred, would materially
affect the investor’s financial condition?



 


Yes ____No ____


 


	If yes, please provide details:  	 
	 	 


 


		8.	The investor is an experienced and sophisticated investor or is advised by a qualified investment
advisor, all as required under the securities laws and regulations.



 


Yes ____No ____


 


		9.	The investor understands the full nature and risk of an investment in the Securities and can afford
the complete loss of the entire investment in the Securities.



 


Yes ____No ____


 


		10.	The investor is able to bear the economic risk of an investment in the Securities for an indefinite
period of time and understands that an investment in the Securities may be illiquid.



 


Yes ____No ____


 


		11.	Does the investor have any other investments or contingent liabilities that the investor reasonably
anticipates could cause the need for sudden cash requirements in excess of cash readily available to the investor?



 


Yes ____No ____


 


	If yes, please explain:  	 
	 	 


 


		12.	Please describe the investor’s experience as an investor (including amounts invested) in
securities, particularly investments in non-marketable and tax incentive securities.



 


		13.	Has the investor participated in other private placements of securities?



 


Yes ____No ____


 


	If yes, please provide detail:  	 


 


		14.	In evaluating the merits and risks of this investment, does the investor intend to rely upon the
advice of the investor’s attorney, accountant or other advisor?



 


Yes ____No ____


 




    	 	B - 4	 



     


    

  


		15.	If the investor is an entity, was it formed for the specific purpose of acquiring the Securities
offered?



 


Yes ____No ____


 


		16.	Manner in which title to Securities is to be held: (circle one)



 


		(a)	Individual Ownership






		(b)	Community Property






		(c)	Joint Tenant with Right of Survivorship (both parties must sign)






		(d)	Partnership






		(e)	Tenants in Common






		(f)	Company






		(g)	Trust






		(h)	Other: _____________________



 


		17.	Further Representations



 


The investor understands that the
Company will be relying on the accuracy and completeness of the investor’s responses to the foregoing questions and the investor
represents and warrants to the Company as follows:


 


		(i)	The answers to the above questions are complete and correct and may be relied upon by the Company
whether or not the offering in which the investor proposes to participate is exempt from registration under the Securities Act
and the securities laws of certain states;



 


		(ii)	The investor will notify the Company immediately of any material change in any statement made herein
occurring prior to the closing of any purchase by the investor of the Securities; and



 


		(iii)	The investor or its management, in case of an entity, has sufficient knowledge and experience in
financial, investment and business matters to evaluate the merits and risks of the prospective investment; and the investor is
able to bear the economic risk of the investment in the Securities and currently could afford a complete loss of such investment.



 


[Signature Page Follows]


 




    	 	B - 5	 



     


    

  


MDNA Life Sciences, Inc.


 


ACCREDITED INVESTOR QUESTIONNAIRE SIGNATURE
PAGE


 


IN WITNESS WHEREOF, the
undersigned has executed this Accredited Investor Questionnaire as of the date set forth below and declares under oath that it
is truthful and correct to the best of the undersigned’s knowledge.


 








	Signature of the Investor or Authorized Signatory of Investor:  	 



 


	Name of Investor:  	 
	 	 
	Title of Authorized Signatory:  	 




 


Date: ________________________________


 


If jointly held:


 





	Signature of the Investor or Authorized Signatory of Investor:  	 



 


	Name of Investor:  	 
	 	 
	Name of Authorized Signatory:	 
	 	 
	Title of Authorized Signatory:  	 




 


Date: ________________________________


 




    	 	B - 6	 



     


    

  


EXHIBIT C


 


MDNA LIFE SCIENCES, INC. 


CERTIFICATE OF DESIGNATIONS OF PREFERENCES,



RIGHTS AND LIMITATIONS 


OF 


SERIES A CONVERTIBLE PREFERRED STOCK 


 


PURSUANT TO SECTION 151 OF THE


DELAWARE GENERAL CORPORATION LAW


 


The undersigned, ____________ and _____________,
do hereby certify that:


 


1. They are the Chairman
and Secretary, respectively, of MDNA Life Sciences, Inc., a Delaware corporation (the “Corporation”).


 


2. The Corporation is authorized
to issue 20,000,000 shares of preferred stock, of which no shares have been designated.


 


3. The following resolutions
were duly adopted by the board of directors of the Corporation (the “Board of Directors”):


 


WHEREAS, the certificate of incorporation of
the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 20,000,000 shares, $0.001
par value per share, issuable from time to time in one or more series;


 


WHEREAS, the Board of Directors is authorized
to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences
of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof,
of any of them; and


 


WHEREAS, it is the desire of the Board of Directors,
pursuant to its authority as aforesaid, to fix the voting powers, full or limited or no voting powers, and such designations, preferences,
rights, qualifications, limitations or restrictions thereof and other matters relating to a series of the preferred stock, which
shall consist of up to Nine Million Ninety Thousand Nine Hundred and Nine (9,090,909) shares of the preferred stock, which the
Corporation has the authority to issue, as follows: NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide
for designation of 9,090,909 shares of preferred stock of the Corporation as its Series A Convertible Preferred Stock (as hereinafter
defined as the “Preferred Stock”) and the issuance of such Preferred Stock for cash or exchange of other securities,
rights or property and does hereby fix and determine the voting powers, full or limited or no voting powers, and such designations,
preferences, rights, qualifications, limitations or restrictions thereof and other matters relating to such Preferred


 




    	 	C - 1	 



     


    

  


TERMS
OF SERIES A PREFERRED STOCK


 


Section 1. Definitions.
For the purposes hereof, the following terms shall have the following meanings:


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.


 


“Alternate
Consideration” shall have the meaning set forth in Section 7(e).


 


“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.


 


“Common
Stock” means the Corporation’s common stock, par value $0.001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed.


 


“Common
Stock Equivalents” means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof
to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time, and/or from time to time, convertible into or exercisable or exchangeable for, or otherwise entitles
the holder thereof to receive, Common Stock.


 


“Conversion
Date” shall have the meaning set forth in Section 6(a).


 


“Conversion
Price” shall have the meaning set forth in Section 6(b).


 


“Conversion
Share” shall have the meaning set forth in Section 7(b).


 


“Corporation”
shall mean MDNA Life Sciences, Inc., a Delaware corporation.


 


“Dividend
Notice Period” shall have the meaning set forth in Section 3(a).


 


“Eligible
Market” means The New York Stock Exchange, the NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Capital Market,
The NASDAQ Global Market, the OTCQB and the OTC Bulletin Board.


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Excluded
Issuance” shall have the meaning set forth in Section 6(d).


 


“Fundamental
Transaction” means that (A) the Corporation shall, directly or indirectly, in one or more related transactions, (i) consolidate
or merge with or into (whether or not the Company is the surviving corporation) another Person or Persons, or (ii) allow another
Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares
of Voting Stock of the Corporation (not including any shares of Voting Stock of the Corporation held by the Person or Persons making
or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (iii)
consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding
shares of Voting Stock of the Corporation (not including any shares of Voting Stock of the Corporation held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase
agreement or other business combination), or (iv) reorganize, recapitalize, or reclassify the Voting Stock of the Corporation or
(B) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange
Act) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly,
of 50% of the aggregate Voting Stock of the Corporation.


 




    	 	C - 2	 



     


    

  


“Holder”
shall have the meaning given such term in Section 2.


 


“Junior
Securities” means the Common Stock and all other Common Stock Equivalents of the Corporation other than those securities
which are explicitly senior or pari passu to the Preferred Stock in, among other rights, dividend rights or liquidation
preference.


 


“Liquidation”
shall have the meaning set forth in Section 5.


 


“Notice
of Conversion” shall have the meaning set forth in Section 6(a).


 


“Original
Issue Date” means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers
of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred
Stock.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Qualified
Public Offering” shall have the meaning set forth in Section 6(d).


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


“Series
A Preferred Stock” shall have the meaning set forth in Section 2.


 


“Stated
Value” shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.


 


“Subsidiary”
means any subsidiary of the Corporation.


 


“Successor
Entity” shall have the meaning set forth in Section 7(e).


 


“Trading
Day” means a day on which an Eligible Market is open for business.


 


“Voting
Stock” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have
the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers or
trustees of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might
have voting power by reason of the happening of any contingency.


 




    	 	C - 3	 



     


    

  


Section 2. Designation,
Amount and Par Value. The series of preferred stock shall be designated as the Series A Preferred Stock (the “Series
A Preferred Stock”) and the number of shares so designated shall be 9,090,909 (which shall not be subject to increase
without the written consent of a majority of the holders of the then outstanding Series A Preferred Stock (each, a “Holder”
and collectively, the “Holders”)). Each share of Series A Preferred Stock shall have a par value of $0.001 per
share and a stated value equal to $0.55 (the “Stated Value”).


 


Section 3. Dividends.


 


a) Dividends
in Kind. Holders shall be entitled to receive, and the Corporation shall pay, cumulative dividends at the rate per share (as
a percentage of the Stated Value per share) of 8% per annum, payable quarterly in arrears on January 15, April 15, July
15 and October 15, beginning on the first date on which shares of Series A Preferred Stock are outstanding, and on each Conversion
Date (with respect only to Series A Preferred Stock being converted) (each such date, a “Dividend Payment Date”)
in the form of duly authorized, validly issued, fully paid and non-assessable shares of Series A Preferred Stock valued at the
Stated Value.


 


b) Dividend
Calculations. Dividends on the Series A Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve
30 calendar day periods, and shall accrue daily commencing on the Original Issue Date, and shall be deemed to accrue from such
date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally
available for the payment of dividends. Dividends shall cease to accrue with respect to any Series A Preferred Stock converted.


 


c) Other Securities.
So long as any Series A Preferred Stock shall remain outstanding, neither the Corporation nor any Subsidiary thereof shall redeem,
purchase or otherwise acquire directly or indirectly any Junior Securities. So long as any Series A Preferred Stock shall remain
outstanding, neither the Corporation nor any Subsidiary thereof shall directly or indirectly pay or declare any dividend or make
any distribution upon, nor shall any distribution be made in respect of, any Junior Securities as long as any dividends due on
the Series A Preferred Stock remain unpaid, nor shall any monies be set aside for or applied to the purchase or redemption (through
a sinking fund or otherwise) of any Junior Securities or shares.


 


Section 4. Voting
Rights. Except as otherwise provided herein or as otherwise required by law, the Series A Preferred Stock shall have no
voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Corporation shall not, without the
affirmative vote of the Holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change
adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend this Certificate of Designation,
(b) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as
defined in Section 5) senior to, or otherwise pari passu with, the Series A Preferred Stock or any other class of
Preferred Stock, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any
rights of the Series A Preferred Stock, (d) increase the number of authorized shares of the Series A Preferred Stock, or (e) enter
into any agreement with respect to any of the foregoing.


 


Section 5. Liquidation.
Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”),
after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the Series A Preferred
Stock shall be entitled to receive, before the holders of any of the Common Stock or other classes of preferred stock of the Corporation
ranking junior thereto, out of the remaining net assets of the Corporation, the amount each holder invested in the Series A Preferred
Stock. After such payment shall have been made in full to the holders of the outstanding Series A Preferred Stock, or funds or
assets necessary for such payment shall have been set aside in trust for the account of the holders of the outstanding Series A
Preferred Stock, so as to be and continue to be available therefor, the holders of the outstanding Series A Preferred Stock shall
be entitled to no further participation in such distribution of the assets of the Corporation on account of their ownership of
Series A Preferred Stock.


 



    	 	C - 4	 



     


    

 


In the event that, after payment or provision
for payment of the debts and other liabilities of the Corporation and any accrued and unpaid dividends of the Series A Preferred
Stock, the remaining net assets of the Corporation are not sufficient to pay the liquidation preference of the holders of the Series
A Preferred Stock, then no such distribution shall be made on account of any shares of any other class or series of capital stock
of the Corporation ranking on a parity with the shares of the Series A Preferred Stock upon such liquidation, unless proportionate
distributive amounts shall be paid on account of each share of the Series A Preferred Stock, ratably, in proportion to the full
distributable amounts for which holders of all such parity shares, including other shares of Series A Preferred Stock, are respectively
entitled upon such liquidation.


 


Section 6. Conversion.


 


a) Conversions
at Option of Holder. Each share of Series A Preferred Stock shall be convertible, at any time and from time to time from and
after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock determined by dividing
the Stated Value of such share of preferred stock by the Conversion Price. Holders shall effect conversions by providing the Corporation
with the form of conversion notice attached hereto as Annex A (a “Notice of Conversion”). Each Notice
of Conversion shall specify the number of shares of Series A Preferred Stock to be converted and the date on which such conversion
is to be effected, which date may not be prior to the date the applicable Holder delivers by facsimile such Notice of Conversion
to the Corporation (such date, the “Conversion Date”). If no Conversion Date is specified in a Notice of Conversion,
the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. Shares of
Series A Preferred Stock converted into Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.


 


b) Conversion
Price. The conversion price for the Series A Preferred Stock shall equal $0.55, subject to adjustment herein (the “Conversion
Price”).


 


c) Reservation
of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its
authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Preferred Stock,
free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders
of the Series A Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall be issuable upon the
conversion of the then outstanding shares of Series A Preferred Stock and payment of dividends hereunder. The Corporation covenants
that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and
nonassessable.


 



    	 	C - 5	 



     


    

 


Section 7. Certain
Adjustments.


 


a) Stock Dividends
and Stock Splits. If the Corporation, at any time, and from time to time, while this Series A Preferred Stock is outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common
Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued
by the Corporation upon conversion of, or payment of a dividend on, the Series A Preferred Stock), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares
of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock,
any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before
such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event.
Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision, combination or re-classification.


 


b) Fundamental
Transaction. If, at any time, and from time to time, while this Series A Preferred Stock is outstanding, the Corporation has
a Fundamental Transaction, then, upon any subsequent conversion of this Series A Preferred Stock, the Holder shall have the right
to receive, for each share of Common Stock issuable upon conversion of the Series A Preferred Stock (“Conversion Share”)
that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the number
of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation,
and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this preferred stock is convertible immediately prior
to such Fundamental Transaction. For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share
of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A Preferred
Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to
the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms
and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’
right to convert such Series A Preferred Stock into Alternate Consideration. The Corporation shall cause any successor entity in
a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume in writing
all of the obligations of the Corporation under this Certificate of Designation pursuant to written agreements in form and substance
reasonably satisfactory to a majority in interest of the Holders and approved by majority in interest of the Holders (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the holder of this preferred stock, deliver to the Holder
in exchange for this Series A Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Series A Preferred Stock which is convertible for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion
of this Series A Preferred Stock prior to such Fundamental Transaction, and with a conversion price which applies the conversion
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
conversion price being for the purpose of protecting the economic value of this Series A Preferred Stock immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to a majority in interest
of the Holders. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation referring
to the “Corporation” shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation
and shall assume all of the obligations of the Corporation under this Certificate of Designation with the same effect as if such
Successor Entity had been named as the Corporation herein.


 



    	 	C - 6	 



     


    

 


c) Calculations.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.


 


d) Anti-dilution.


 


(i) The Conversion
Price will be subject to adjustment on a “ weighted average” basis such that if the Corporation issues Common Stock
or Common Stock equivalents at a price per share less than the then applicable Conversion Price for the Series A Preferred Stock,
the Conversion Price of the Series A Preferred Stock shall be reduced based upon the following formula: the “weighted average”
formula is calculated to reduce the Conversion Price in effect prior to such issuance or sale to a price determined by dividing
(A) an amount equal to the sum of (i) the number of shares of common stock outstanding immediately prior to such issuance or sale,
multiplied by the then applicable conversion price and (ii) the consideration, if any, received by the Corporation upon such issuance
or sale, by (B) the total number of shares of common stock outstanding immediately after such issuance or sale.


 


(ii) Exceptions.
There will be no adjustment to the Conversion Price of the Series A Preferred Stock for the following kinds of issuances notwithstanding
that the price per share may be less than the then-applicable Conversion Price: (i) shares of Common Stock issued upon conversion
of the Series A Preferred Stock; (ii) shares of Common Stock or options, warrants or other rights issued to employees, consultants
or directors in accordance with plans, agreements or similar arrangements unanimously approved by the Board of Directors; (iii) shares
of Common Stock issued upon exercise of options, warrants or convertible securities existing on or prior to any closing of the
sale of Series A Preferred Stock (the “Offering”); (iv) shares of Common Stock issued as a dividend or distribution
on the Series A Preferred Stock or for which adjustment is otherwise made pursuant to the Company’s charter documents (e.g.,
stock splits); (v) shares of Common Stock issued for consideration other than cash pursuant to a strategic relationship, joint
venture, merger, consolidation, acquisition, or similar business combination approved by the Board of Directors; (vi) shares of
Common Stock issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing
from a bank or similar financial institution approved by the Board of Directors; (vii) shares of Common Stock issued with respect
to securities outstanding as of the issuance date of any sale of Series A Preferred Stock; (vii) shares of Common Stock issued
in connection with the Offering, including to any Placement Agent; (viii) shares of Common Stock issued or issuable in connection
with any settlement approved by the Board of Directors; (ix) shares of Common Stock issued or issuable in connection with
sponsored research, collaboration, technology license, development, OEM, marketing or other similar arrangements or strategic partnerships
unanimously approved by the board of directors; (x) shares of Common Stock issued to suppliers of goods or services in connection
with the provision of goods or services pursuant to transactions unanimously approved by the Board of Directors; or (xi) shares
of Common Stock that are otherwise excluded by consent of the holders of a majority of the Series A Convertible Preferred Stock
(the “Excluded Issuances”).


 



    	 	C - 7	 



     


    

 


e) Notice
to the Holders.


 


i. Adjustment
to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation
shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment.


 


ii. Notice to
Allow Conversion by Holder. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any
sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common
Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be
filed at each office or agency maintained for the purpose of conversion of this Series A Preferred Stock, and shall cause to be
delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least twenty (20) calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights
or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or
any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in
such notice. The Holder shall remain entitled to convert the Series A Preferred Stock (or any part hereof) during the 20-day period
commencing on the date of such notice through the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.


 



    	 	C - 8	 



     


    

 


Section 8. Forced
Conversion. Notwithstanding anything herein to the contrary, the Corporation shall have the right upon fifteen (15) days
written notice, to require the Holder to convert the Series A Preferred Stock to Common Stock at the Conversion Price at any time
in the event of any of the following:


 


i. the Corporation
shall undertake an initial public offering under any applicable securities legislation or the Common Stock shall become actively
traded on any Eligible Market;


 


ii. in the event
of any amalgamation, merger, consolidation or similar transaction with any corporation dealing at arm’s length with the Corporation
or the Corporation entering into any agreement that proposes or provides for any of the foregoing;


 


iii. in the event
the Corporation shall enter into any agreement for the sale of a majority of its assets which transaction is approved by the shareholders
of the Corporation holding shares representing a majority of the total votes of the Common Stock of the Corporation (calculated
without reference to the Common Stock underlying the Series A Preferred Stock); and


 


iv. in the event
any Fundamental Transaction is proposed, offered or entered into, which Fundamental Transaction is conditional upon the bidder
acquiring all of the issued and outstanding shares and which bid is acceptable to the shareholders of the Corporation holding shares
representing a majority of the total votes of the Common Stock of the Corporation (calculated without reference to any Common Stock
underlying the Series A Preferred Stock).


 


Section 9. Negative
Covenants. As long as any shares of Series A Preferred Stock are outstanding, the Corporation shall not, and shall not
permit any of the Subsidiaries to, directly or indirectly:


 


a) amend its
charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially and
adversely affects any rights of the Holders;


 


b) pay cash dividends
or distributions on Junior Securities of the Corporation;


 


c) enter into
any agreement with respect to any of the foregoing.


 


Section 10. Ranking.
As long as any shares of the Series A Preferred Stock remain outstanding, the Corporation shall not, without obtaining the prior
written consent of the holders of at least a majority of the shares of the Series A Preferred Stock then outstanding, create, authorize
or issue any other class or series of capital stock of the Corporation, the terms of which provide that such class or series shall
rank prior to, or on parity with, the Series A Preferred Stock in respect to rights upon dissolution, liquidation or winding up
of the Corporation; provided, however, the Corporation may at any time create, authorize or issue, without the consent of any of
the holders of the Series A Preferred Stock, other classes or series of capital stock which rank junior to, or on parity with,
the Series A Preferred Stock in respect to dissolution, liquidation or winding up of the Corporation.


 


Section 11. Miscellaneous.


 


a) Absolute
Obligation. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the
obligation of the Corporation, which is absolute and unconditional, to pay accrued dividends on the shares of Series A Preferred
Stock at the time, place, and rate, and in the coin or currency, herein prescribed.


 



    	 	C - 9	 



     


    

 


b) Lost or
Mutilated Preferred Stock Certificate. If a Holder’s Series A Preferred Stock certificate shall be mutilated, lost, stolen
or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of
Series A Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction
of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.


 


c) Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation
shall be governed by and construed and enforced exclusively in accordance with the internal laws of the State of Delaware, without
regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation,
enforcement and defense of the transactions contemplated by this Certificate of Designation (whether brought against a party hereto
or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal
courts sitting in Delaware (the “DE Courts”). Each party hereto hereby irrevocably submits to the exclusive
jurisdiction of the DE Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of such DE Courts, or such DE Courts are improper or inconvenient venue for
such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any other manner permitted by applicable law.


 


d) Waiver.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as
or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate
of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to
any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or
any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of
Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.


 


e) Amendments.
This Statement of Designation may be amended only upon both (i) the affirmative vote of holders holding not less than a majority
of the Series A Preferred Stock then outstanding at the time such amendment is proposed, and (ii) the affirmative vote of not less
than a majority of the directors of the Corporation then holding office and entitled to vote on such amendment.


 


f) Severability.
If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable
to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
rate of interest permitted under applicable law.


 



    	 	C - 10	 



     


    

 


g) Next Business
Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.


 


h) Headings.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not
be deemed to limit or affect any of the provisions hereof.


 


i) Status
of Converted Series A Preferred Stock. If any shares of Series A Preferred Stock shall be converted or reacquired by the Corporation,
such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series
A Preferred Stock.


 


*********************


 


RESOLVED, FURTHER, that
the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they
hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in
accordance with the foregoing resolution and the provisions of Delaware law.


 





	IN WITNESS WHEREOF, the undersigned have executed this Certificate this ____ day of ________ 2017.	 


 


	 	 	 	 	 
	Name:	 	 	Name:	 
	Title:  	Chairman	 	Title:  	Secretary




 



    	 	C - 11	 



     


    

  


EXHIBIT D


 


FORM
OF CLASS A WARRANT

MDNA LIFE SCIENCES, INC.

WARRANT TO PURCHASE COMMON STOCK


 


NEITHER THIS SECURITY NOR THE SECURITIES FOR
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.


 


COMMON
STOCK PURCHASE WARRANT


 


MDNA
LIFE SCIENCES, inc.


 


	
         Class A Warrant Number: ____
	Issue Date:  ______, 201_


 


THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, ____________ (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the seventh
(7th) anniversary of the date of the initial closing of the offering pursuant to which this Warrant is being issued
(the “Termination Date”) but not thereafter, to subscribe for and purchase from MDNA Life Sciences, Inc., a
Delaware Company (the “Company”), up to _______________ shares (the “Warrant Shares”)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).


 


Section 1.              Definitions.


 


a)            “Business
Day” means any day other than (a) a Saturday or Sunday and (b) any day on which banks are required or permitted to be
closed in New York, New York.


 


b)            “Commission”
means the United States Securities and Exchange Commission.


 


c)            “Common
Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.


 


d)            “Common
Stock Equivalents” means any securities of the Company or the subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive, Common Stock.


 



    	 	D - 1	 



     


    

 


e)            “Person”
means an individual or Company, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


f)            “Registration
Statement” means a registration statement covering the resale by the Holder of the Warrant Shares.


 


g)            “Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.


 


h)            “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


i)            “Trading
Day” means a day on which the principal Trading Market is open for trading.


 


j)            “Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange, the OTCQB, the OTC Bulletin Board or the OTC Pink (or any successors to any of the foregoing).


 


k)            “Voting
Stock” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have
the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers or
trustees of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might
have voting power by reason of the happening of any contingency


 


l)            “VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), or (b) in all other cases, the fair market value of
a share of Common Stock as determined by an independent appraiser selected in good faith by the Company, the fees and expenses
of which shall be paid by the Company.


 


Section 2.              Exercise.


 


a)            Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of an executed copy of the Notice of Exercise Form annexed hereto; and, within three (3) Trading Days
of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise
Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank or, if available,
pursuant to the cashless exercise procedure specified in Section 2(c) below. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to
the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company,
failure, however, to deliver such certificate shall not affect the rights of the Holder herein to, among other things, exercise
this Warrant and receive the Warrant Shares in accordance with this Warrant. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise Form within three (3) Business Days of receipt of such notice. In the event of
any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.


 



    	 	D - 2	 



     


    

 


b)            Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $0.61 subject to adjustment hereunder (the
“Exercise Price”).


 


c)            Cashless
Exercise. If at any time while the Common Stock is listed or quoted on a Trading Market there is no Registration Statement
effective and available for use by the Holder to resell the Warrant Shares immediately upon exercise of this Warrant, this Warrant
may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall
be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:


 


		(A) =	the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise
this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;



 


		(B) =	the Exercise Price of this Warrant, as adjusted hereunder; and



 


		(X) =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.



 


d)            Mechanics
of Exercise.


 


i.       Delivery
of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Transfer Agent to the
Holder by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading
Days after the latest of (A) the delivery to the Company of the Notice of Exercise Form, (B) surrender of this Warrant (if required),
and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise) (such date, the “Warrant
Share Delivery Date”). This Warrant shall be deemed to have been exercised on the first date on which all of the foregoing
have been delivered to the Company. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated
to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant
has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise) and all taxes required to be paid
by the Holder, if any, having been paid.


 



    	 	D - 3	 



     


    

 


ii.       Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant.


 


iii.       Failure
to Deliver Certificates. If, in the case of any Notice of Exercise, such certificate or certificates are not delivered to or
as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the
Company at any time on or before its receipt of such certificate or certificates, to rescind such Notice of Exercise, in which
event the Company shall promptly return to the Holder any Warrant certificate delivered to the Company and the Holder shall promptly
return to the Company the Common Stock certificates issued to such Holder pursuant to the rescinded Notice of Exercise.


 


iv.       No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.


 


v.       Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.


 


Section 3.              Certain
Adjustments.


 


a)            Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on its shares of Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.


 



    	 	D - 4	 



     


    

 


b)            Subsequent
Equity Sales. If at any time while this Warrant is outstanding, the Company or any subsidiary, as applicable, sells or grants
any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant
or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any person or entity to
acquire shares of Common Stock at an effective price per share that is lower than the then Exercise Price (such lower price, the
“Base Exercise Price” and such issuances, collectively, a “Dilutive Issuance”), then the
Exercise Price shall be reduced on a “ weighted average” basis such that if the Company issues Common Stock or Common
Stock Equivalents at a price per share less than the then applicable Exercise Price the Exercise Price shall be reduced based upon
the following formula: the “weighted average” formula is calculated to reduce the Exercise Price in effect prior to
such issuance or sale to a price determined by dividing (A) an amount equal to the sum of (i) the number of shares of common stock
outstanding immediately prior to such issuance or sale, multiplied by the then applicable exercise price and (ii) the consideration,
if any, received by the Company upon such issuance or sale, by (B) the total number of shares of common stock outstanding immediately
after such issuance or sale. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. The
Company shall notify the Holder in writing, no later than one Business Day following the issuance of any Common Stock or Common
Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable reset price, exchange
price, exercise price and other pricing terms (such notice, the “Dilutive Issuance Notice”). For purposes of
clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon the occurrence
of any Dilutive Issuance, the Holder is entitled to the benefit of the reduced Exercise Price on or after the date of such Dilutive
Issuance, regardless of whether the Holder accurately refers to the Base Exercise Price in the Notice of Exercise. There will be
no adjustment arising from the foregoing for the following kinds of issuances notwithstanding that the price per share may be less
than the then-applicable exercise price: (i) shares of Common Stock issued upon conversion of the Company’s Series A
Preferred Stock; (ii) shares of Common Stock or options, warrants or other rights issued to employees, consultants or directors
in accordance with plans, agreements or similar arrangements unanimously approved by the Board of Directors; (iii) shares
of Common Stock issued upon exercise of options, warrants or convertible securities existing on or prior to any closing of the
offering pursuant to which this Warrant is being issued ; (iv) shares of Common Stock issued as a dividend or distribution
on the Company’s Series A Preferred Stock or for which adjustment is otherwise made pursuant to the Company’s charter
documents (e.g., stock splits); (v) shares of Common Stock issued for consideration other than cash pursuant to a strategic
relationship, joint venture, merger, consolidation, acquisition, or similar business combination approved by the Board; (vi) shares
of Common Stock issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing
from a bank or similar financial institution approved by the Board; (vii) shares of Common Stock issued with respect to securities
outstanding as of any closing date under the offering under which the Warrant was issued; (viii) shares of Common Stock issued
in connection with the offering or this Warrant pursuant to which these securities are issued, including to any placement agent
used in such offering; (ix) shares of Common Stock issued or issuable in connection with any settlement approved by the board
of directors; (x) shares of Common Stock issued or issuable in connection with sponsored research, collaboration, technology
license, development, OEM, marketing or other similar arrangements or strategic partnerships unanimously approved by the board
of directors; (xi) shares of Common Stock issued to suppliers of goods or services in connection with the provision of goods
or services pursuant to transactions unanimously approved by the Board of Directors; or (xii) shares of Common Stock that
are otherwise excluded by consent of the holders of a majority of the Series A Preferred Stock (the “Excluded Issuances”).


 



    	 	D - 5	 



     


    

 


c)             Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or
party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other
business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number of shares of Common Stock of the
successor or acquiring Company or of the Company, if it is the surviving Company, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common
Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(c) prior to
such Fundamental Transaction. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to
the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been
named as the Company herein.


 


d)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.


 



    	 	D - 6	 



     


    

 


e)            Notice
to Holder.


 


i.       Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall mail
to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts
requiring such adjustment.


 


ii.       Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, excluding a stock dividend as contemplated in Section 3(a), (B) the Company shall declare a special nonrecurring
cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other securities, cash or property (in each case, excluding
any event contemplated in Section 3(a)), or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall
not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice,
except as may otherwise be expressly set forth herein.


 


Section 4.              Transfer
of Warrant.


 


a)            Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and
all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed
by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.


 



    	 	D - 7	 



     


    

 


b)            New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original
issue date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.


 


c)            Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.


 


d)            Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be eligible for resale without volume or manner-of-sale restrictions or current public information requirements
pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this
Warrant, as the case may be, provide to the Company an opinion of counsel selected by the Holder or transferee and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Securities under the Securities Act.


 


e)            Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.


 


Section 5.               Miscellaneous.


 


a)            No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).


 


b)            Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.


 


c)            Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.


 



    	 	D - 8	 



     


    

 


d)            Authorized
Shares. The Company covenants that, during the period commencing on the Initial Exercise Date and through the date that the
Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide
for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which
the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase
rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).


 


e)            Governing
Law. This Warrant shall be governed by and construed solely and exclusively under and pursuant to the laws of the State of
Delaware as applied to agreements among Delaware residents entered into and to be performed entirely within Delaware.


 


f)            Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.


 


g)            Nonwaiver.
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of
such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder
terminate on the Termination Date.


 


h)            Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company at the address
set forth in the Company’s records.


 


i)             Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.


 


j)            Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.


 


k)            Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.


 


l)            Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.


 



    	 	D - 9	 



     


    

 


IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.


 


	 	MDNA LIFE SCIENCES, INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:




 






    	 	D - 10	 



     


    

 


Exhibit A


 


EXERCISE
NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

MDNA LIFE SCIENCES, INC.


 


NOTICE
OF EXERCISE


 


		To:	MDNA LIFE SCIENCES, INC.



 


(1)           The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.


 


(2)           Payment
shall take the form of (check applicable box):


 


[ ] in lawful money of the United
States; or


 


[ ] the cancellation of such number
of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).


 


(3)           Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:


 


_______________________________


 


The Warrant Shares shall be delivered by physical
delivery of a certificate to:


 


_______________________________

_______________________________

_______________________________


 


(4)           Accredited
Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities
Act of 1933, as amended.


 


[SIGNATURE OF HOLDER]


 


	Name of Investing Entity:	 	 



 


	Signature of Authorized Signatory of Investing
Entity:	 



 


	Name of Authorized Signatory: 	 
	 	 
	Title of Authorized Signatory:  	 




 


Date: ___________________________________________


 



    	 	D - 11	 



     


    

 


Exhibit B


 


ASSIGNMENT
FORM


 


(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)


 


FOR VALUE RECEIVED, [____]
all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to


 


_______________________________________________
whose address is


 


_______________________________________________________________.


 


_______________________________________________________________


 


	 	Dated:  ______________, _______


 


	 	Holder’s Signature:	 	 
	 	Holder’s Address:	 	 
	 	 	 	 




 


Signature Guaranteed: ___________________________________________


 


NOTE: The signature to this Assignment Form
must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.


 



    	 	D - 12	 



     


    

 


Exhibit E


 






    	 	E - 1	 



     


    

 


Certificate
of Incorporation


 





	State of Delaware	 
	Secretary of State	 
	Division of Corporations	 
	Delivered 05:04 PM 11/03/2014	 
	FILED 04:56 PM 11/03/2014	 
	SPV 141365617 - 5632728 FILE	 


 


CERTIFICATE OF INCORPORATION


 


OF


 


MDNA LIFE SCIENCES INC.


 


* * * *


 


		FIRST:	The
                                         name of the corporation is MDNA Life Sciences Inc. (the “Corporation”).



 


		SECOND:	The address of its registered office in the State of Delaware is Corporation Trust Center, 1209
Orange Street in the City of Wilmington, County of New Castle. The name of its registered agent at such address is The Corporation
Trust Company.



 


		THIRD:	The purpose or purposes of the Corporation shall be to engage in any lawful act or activity for
which corporations may be organized under the General Corporation Law of the State of Delaware.



 


		FOURTH:	The aggregate number of shares which the Corporation is authorized to issue is one hundred twenty
million (120,000,000), divided into classes as follows:



 


		A.	One
                                         hundred million (100,000,000) shares of common stock, $.001 par value per share (hereinafter
                                         called the “Common Stock”);



 


		B.	Twenty million (20,000,000) shares of preferred stock, $.001 par value per share, to be issued
in series (the “Preferred Stock”).



 


The following is a statement
of the designations, powers, preferences and rights, and the qualifications, limitations or restrictions with respect to the Preferred
Stock of the Corporation: The shares of Preferred Stock may be issued in one or more series, and each series shall be so designated
as to distinguish the shares thereof from the shares of all other series. Authority is hereby expressly granted to the Board of
Directors of the Corporation to fix, subject to the provisions herein set forth, before the issuance of any shares of a particular
series, the number, designations and relative rights, preferences, and limitations of the shares of such series including (1) voting
rights, if any, which may include the right to vote together as a single class with the Common Stock and any other series of the
Preferred Stock with the number of votes per share accorded to shares of such series being the same as or different from that accorded
to such other shares, (2) the dividend rate per annum, if any, and the terms and conditions pertaining to dividends and whether
such dividends shall be cumulative, (3) the amount or amounts payable upon such voluntary or involuntary liquidation, (4) the redemption
price or prices, if any, and the terms and conditions of the redemption, (5) sinking fund provisions, if any, for the redemption
or purchase of such shares, (6) the terms and conditions on which such shares are convertible, in the event the shares are to have
conversion rights, and (7) any other rights, preferences and limitations pertaining to such series which may be fixed by the Board
of Directors pursuant to the Delaware General Corporation Law.


 


		FIFTH:	In furtherance and not in limitation of the powers conferred by statute, the Board of Directors
is expressly authorized to make, alter or repeal the by-laws of the Corporation.



 


		SIXTH:	A
                                         director of the Corporation shall not be personally liable to the Corporation or
                                         its stockholders for monetary damages for breach of fiduciary duty as a director except
                                         for liability (i) for any breach of the director's duty of loyalty to the Corporation
                                         or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional
                                         misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General
                                         Corporation Law, or (iv) for any transaction



 



    	 	E - 2	 



     


    

 


	 	Delaware	PAGE 1


The first State


 


I, JEFFREY W. BULLOCK, SECRETARY OF STATE
OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF "MDNA
LIFE SCIENCES INC.", FILED IN THIS OFFICE ON THE THIRD DAY OF NOVEMBER, A.D. 2014, AT 4:56 O'CLOCK P.M. 


 


A FILED COPY OF THIS CERTIFICATE HAS BEEN
FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.












 



    	 	E - 3	 



     


    

 


Exhibit F


 


Bylaws of MDNA Life Sciences Inc.


 


BYLAWS OF 


 


MDNA LIFE SCIENCES INC. 


 


INCORPORATED UNDER THE LAWS OF THE STATE
OF DELAWARE 


 


ARTICLE I 


 


OFFICES AND RECORDS 


 


Section 1.1. DELAWARE OFFICE. The principal
office of MDNA Life Sciences Inc. (the “Corporation”) in the State of Delaware shall be located in the City of Wilmington,
County of New Castle, and the name and address of its registered agent is The Corporation Trust Company, 1209 Orange Street, Wilmington,
Delaware.


 


Section 1.2. OTHER OFFICES. The Corporation
may have such other offices, either within or without the State of Delaware, as the Board of Directors may designate or as the
business of the Corporation may from time to time require.


 


Section 1.3. BOOKS AND RECORDS. The books and
records of the Corporation may be kept at the Corporation's headquarters or at such other locations outside the State of Delaware
as may from time to time be designated by the Board of Directors.


 


ARTICLE II 


 


STOCKHOLDERS 


 


Section 2.1. ANNUAL MEETINGS. An annual meeting
of stockholders shall be held for the election of directors at such date, time and place, either within or without the State of
Delaware, as may be designated by resolution of the Board of Directors from time to time. Any other proper business may be transacted
at the annual meeting.


 


Section 2.2 SPECIAL MEETINGS. Special meetings
of the stockholders, for any purpose or purposes described in the notice of meeting, may be called by the president, or by the
Board of Directors, and shall be called by the president at the request of the holders of not less than one-tenth of all outstanding
shares of the Corporation entitled to vote on any issue at the meeting.


 


Section 2.3. NOTICE OF MEETINGS. Whenever stockholders
are required or permitted to take any action at a meeting, a written notice of the meeting shall be given that shall state the
place, date and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called.
Unless otherwise provided by law, the Certificate of Incorporation or these Bylaws, the written notice of any meeting shall be
given not less than ten or more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting.
If mailed, such notice shall be deemed to be given when deposited in the United States mail, postage prepaid, directed to the stockholder
at his or her address as it appears on the records of the Corporation.


 



    	 	F - 1	 



     


    

 


Section 2.4. ADJOURNMENTS. Any meeting of stockholders,
annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of
any such adjourned meeting if the time and place thereof is announced at the meeting at which the adjournment is taken. At the
adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment
is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned
meeting shall be given to each stockholder of record entitled to vote at the meeting.


 


Section 2.5. QUORUM. Except as otherwise provided
by law, the Certificate of Incorporation or these Bylaws, at each meeting of stockholders the presence in person or by proxy of
the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding shares of stock
entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. In the absence of a quorum, the stockholders
so present may, by majority vote, adjourn the meeting from time to time in the manner provided in Section 2.4 of these Bylaws until
a quorum shall attend. Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the shares
entitled to vote in the election of directors of such other corporation is held, directly or


 


indirectly, by the Corporation, shall neither
be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the
Corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity.


 


Section 2.6. ORGANIZATION. Meetings of stockholders
shall be presided over by the Chairman of the Board, or in his or her absence by the President, or in the absence of the foregoing
persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen at the meeting.
The Secretary shall act as secretary of the meeting, but in his or her absence the chairman of the meeting may appoint any person
to act as secretary of the meeting.


 


Section 2.7. VOTING.


 


(a) Except as otherwise provided by law, the
Certificate of Incorporation, or these Bylaws, any corporate action, other than the election of Directors, the affirmative vote
of the majority of shares entitled to vote on that matter and represented either in person or by proxy at a meeting of stockholders
at which a quorum is present shall be the act of the stockholders of the Corporation.


 


(b) Unless otherwise provided for in the Certificate
of Incorporation of the Corporation, Directors will be elected by a majority of the votes cast by the shares, present in person
or by proxy, entitled to vote in the election at a meeting at which a quorum is present and each stockholder entitled to vote has
the right to vote the number of shares owned by him or her for as many persons as there are Directors to be elected. The Board
of Directors may at any time amend this provision to reduce the number of votes cast for the election of a director to a plurality
of the votes cast in the manner provided immediately above.


 


(c) Except as otherwise provided by statute,
the Certificate of Incorporation, or these Bylaws, at each meeting of stockholders, each stockholder of the Corporation entitled
to vote thereat, shall be entitled to one vote for each share registered in his or her name on the books of the Corporation.


 


Section 2.8 PROXIES. Each stockholder entitled
to vote or to express consent or dissent without a meeting, may do so either in person or by proxy, so long as such proxy is executed
in writing by the stockholder himself or herself, or by his or her attorney-in-fact thereunto duly authorized in writing. Every
proxy shall be revocable at will unless the proxy conspicuously states that it is irrevocable and the proxy is coupled with an
interest. A telegram, telex, cablegram, or similar transmission by the stockholder, or as a photographic, photostatic, facsimile,
shall be treated as a valid proxy, and treated as a substitution of the original proxy, so long as such transmission is a complete
reproduction executed by the stockholder. No proxy shall be valid after the expiration of three years from the date of its execution,
unless otherwise provided in the proxy. Such instrument shall be exhibited to the Secretary at the meeting and shall be filed with
the records of the Corporation.


 



    	 	F - 2	 



     


    

 


Section 2.9 ACTION WITHOUT A MEETING. Unless
otherwise provided for in the Certificate of Incorporation of the Corporation, any action to be taken at any annual or special
stockholders’ meeting, may be taken without a meeting, without prior notice and without a vote if a written consent or consents
is/are signed by the stockholders of the Corporation having not less than the minimum number of votes necessary to authorize or
take such action at a meeting at which all shares entitled to vote thereat were present and voted is delivered by hand or by certified
or registered mail, return receipt requested, to the Corporation to its principal place of business or an officer or agent of the
Corporation having custody of the books in which proceedings of stockholders’ meetings are recorded.


 


Section 2.10. FIXING DATE FOR DETERMINATION
OF STOCKHOLDERS OF RECORD. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any
meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment
of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which
the resolution fixing the record date is adopted by the Board of Directors and which record date: (i) in the case of determination
of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law,
not be more than sixty nor less than ten days before the date of such meeting and (ii) in the case of any other action, shall not
be more than sixty days prior to such other action. If no record date


 


is fixed: (i) the record date for determining
stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding
the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which
the meeting is held and (ii) the record date for determining stockholders for any other purpose shall be at the close of business
on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the
Board of Directors may fix a new record date for the adjourned meeting.


 


Section 2.11. LIST OF STOCKHOLDERS ENTITLED
TO VOTE. The Secretary shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders
entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of
shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose
germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place
within the city where the meeting is to be held, which place shall be specified in the notice of the meeting or, if not so specified,
at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during
the whole time thereof and may be inspected by any stockholder who is present. The stock ledger shall be the only evidence as to
which stockholders are entitled to examine the stock ledger, the list of stockholders or the books of the Corporation, or to vote
in person or by proxy at any meeting of stockholders.


 



    	 	F - 3	 



     


    

 


Section 2.12. CONDUCT OF MEETINGS. The Board
of Directors of the Corporation may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders
as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors,
the chairman of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations and procedures
and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules,
regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include,
without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures
for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the
meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the
chairman of the meeting shall determine; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof;
and (v) limitations on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board
of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules
of parliamentary procedure.


 


Section 2.13. INSPECTORS OF ELECTIONS; OPENING
AND CLOSING THE POLLS. The Board of Directors by resolution may appoint one or more inspectors, which inspector or inspectors may
include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents
or representatives of the Corporation, to act at the meeting and make a written report thereof. One or more persons may be designated
as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to act, or if
all inspectors or alternates who have been appointed are unable to act, at a meeting of stockholders, the chairman of the meeting
shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging his or her duties, shall take and
sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.
The inspectors shall have the duties prescribed by the General Corporation Law of the State of Delaware. The chairman of the meeting
shall fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which
the stockholders will vote at a meeting.


 


ARTICLE III 


 


BOARD OF DIRECTORS 


 


Section 3.1. GENERAL POWERS. The business and
affairs of the Corporation shall be managed by or under the direction of its Board of Directors. In addition to the powers and
authorities by these Bylaws expressly conferred upon them, the Board of Directors may exercise all such powers of the Corporation
and do all such lawful acts and things as are not by law, by the Certificate of Incorporation or by these Bylaws required to be
exercised or done by the stockholders.


 


Section 3.2. NUMBER; QUALIFICATIONS. The Board
of Directors need not be composed of a particular number of members nor must such number be within any particular range, unless
the Certificate of Incorporation, an amendment to these Bylaws or the Board of Directors shall otherwise provide. The number of
Directors shall until such time, if ever, be determined from time to time by resolution of the Board of Directors. Directors need
not be stockholders or residents of the State of Delaware.


 


Section 3.3. ELECTION, RESIGNATION. The first
Board of Directors shall hold office until the first annual meeting of stockholders and until their successors have been duly elected
and qualified or until there is a decrease in the number of Directors. Thereafter, each Director will be elected at the annual
meeting of stockholders and shall hold office until the annual meeting of the stockholders next succeeding his or her election,
or until his or her prior death, resignation or removal. Any Director may resign at any time upon written notice to the Board of
Directors, the President or the Secretary of the Corporation. Such resignation shall be effective upon receipt unless the notice
specifies a later time for that resignation to become effective.


 



    	 	F - 4	 



     


    

 


Section 3.4. VACANCIES. Any newly created directorship
resulting from an increase in the authorized number of Directors or any vacancy occurring in the Board of Directors by reason of
death, resignation, retirement, disqualification, removal from office or any other cause may be filled by the affirmative vote
of the remaining members of the Board of Directors, though less than a quorum of the Board of Directors, and each Director so elected
shall hold office until the expiration of the term of office of the Director whom he or she has replaced or until his or her successor
is elected and qualified. If there are no Directors in office, then an election of Directors may be held in the manner provided
by statute. No decrease in the number of Directors constituting the whole Board shall shorten the term of any incumbent Director.


 


Section 3.5. REGULAR MEETINGS. Regular meetings
of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of
Directors may from time to time determine, and if so determined notices thereof need not be given.


 


Section 3.6. SPECIAL MEETINGS. Special meetings
of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the Chairman
of the Board, the President, the Secretary, or by any two members of the Board of Directors. Notice of the date, time and place
of a special meeting of the Board of Directors shall be delivered by the person or persons calling the meeting personally, by facsimile
or by telephone to each Director or sent by first-class mail or telegram, charges prepaid, addressed to each Director at that Directors'
address as it is shown on the records of the Corporation. If the notice is mailed, it shall be deposited in the United States mail
at least four days before the time of the holding of the meeting. If the notice is delivered personally or by telephone or telegraph,
it shall be delivered at least forty-eight hours before the time of the holding of the special meeting. If by facsimile transmission,
such notice shall be transmitted at least twenty-four hours before the time of holding of the special meeting. Any oral notice
given personally or by telephone may be communicated either to the Director or to a person at the office of the Director who the
person giving the notice has reason to believe will promptly communicate it to the Director. The notice need not specify the purpose
or purposes of the special meeting or the place of the special meeting, if the meeting is to be held at the principal office of
the Corporation.


 


Section 3.7. TELEPHONIC MEETINGS PERMITTED.
Members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting thereof
by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting
can hear each other, and participation in a meeting pursuant to this Bylaw shall constitute presence in person at such meeting.


 


Section 3.8. QUORUM; VOTE REQUIRED FOR ACTION;
ADJOURNMENT. At all meetings of the Board of Directors a majority of the whole Board of Directors shall constitute a quorum for
the transaction of business. Except in cases in which the Certificate of Incorporation or these Bylaws otherwise provide, the
vote of a majority of the Directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.
A majority of the Directors present, whether or not a quorum, may adjourn any meeting to another time and place. Notice of the
time and place of holding an adjourned meeting need not be given unless the meeting is adjourned for more than twenty-four hours.
If the meeting is adjourned for more than twenty-four hours, then notice of the time and place of the adjourned meeting shall
be given to the Directors who were not present at the time of the adjournment in the manner specified in Section 3.6.


 


Section 3.9. ORGANIZATION. Meetings of the Board
of Directors shall be presided over by the Chairman of the Board, or in his or her absence by a chairman chosen at the meeting.
The Secretary shall act as secretary of the meeting, but in his or her absence the chairman of the meeting may appoint any person
to act as secretary of the meeting.


 



    	 	F - 5	 



     


    

 


Section 3.10. INFORMAL ACTION BY DIRECTORS.
Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at
any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board
of Directors or such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the
minutes of proceedings of the Board of Directors or such committee.


 


Section 3.11. FEES AND COMPENSATION OF DIRECTORS.
Directors and members of committees may receive such compensation, if any, for their services and such reimbursement of expenses
as may be fixed or determined by resolution of the Board of Directors. This Section 3.11 shall not be construed to preclude any
Director from serving the Corporation in any other capacity as an officer, agent, employee or otherwise and receiving compensation
for those services.


 


Section 3.12 REMOVAL. One or more or all the
Directors of the Corporation may be removed for cause at any time by the stockholders, at a special meeting of the stockholders
called for that purpose, provided however, such Director shall not be removed if the Certificate of Incorporation or Bylaws provides
that its Directors shall be elected by cumulative voting and there are a sufficient number of shares cast against his or her removal,
which if cumulatively voted at an election of Directors would be sufficient to elect him or her.


 


ARTICLE IV 


 


COMMITTEES 


 


Section 4.1. COMMITTEES. The Board of Directors
may designate from among its members one or more standing or special committees, each committee to consist of one or more of the
Directors of the Corporation. The Board of Directors may designate one or more Directors as alternate members of any committee,
who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member
of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or she
or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of
any such absent or disqualified member. Any such committee, to the extent permitted by law and to the extent provided in the resolution
of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management
of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which
may require it.


 


Section 4.2. COMMITTEE RULES. Unless the Board
of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules for the conduct
of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors
conducts its business pursuant to Article III of these Bylaws.


 


Section 4.3. MINUTES OF MEETINGS. All committees
appointed in accordance with Section 4.1 shall keep regular minutes of their meetings and shall cause them to be recorded in books
kept for that purpose in the office of the Corporation.


 


ARTICLE V 


 


OFFICERS 


 


Section 5.1. DESIGNATIONS. The officers of the
Corporation shall be a Chairman of the Board, a President, a Secretary, Chief Financial Officer and, at the discretion of the Board
of Directors, one or more Directors and one or more Vice-Presidents (one or more of whom may be Executive Vice-Presidents). The
Board of Directors shall appoint all officers. Any two or more offices may be held by the same individual.


 



    	 	F - 6	 



     


    

 


Section 5.2. APPOINTMENT AND TERM OF OFFICE.
The officers of the Corporation shall be appointed annually by the Board of Directors at the first meeting of the Board of Directors
held after each annual meeting of the stockholders. Each officer shall hold office until a successor shall have been appointed
and qualified, or until such officer's earlier death, resignation or removal.


 


Section 5.3. POWERS AND DUTIES. If the Board
appoints persons to fill the following positions, such officers shall have the power and duties set forth below:


 


(a) THE CHAIRMAN: The Chairman shall have general
control and management of the Board of Directors and may also be the President of the Corporation. He or she shall preside at all
meetings of the Board of Directors at which he or she is present. He or she shall have such other powers and perform such other
duties as from time to time may be conferred or imposed upon him or her by the Board of Directors.


 


(b) THE PRESIDENT: The President of the Corporation
shall be generally responsible for the proper conduct and the day to day operations of the business of the Corporation. He or she
shall possess power to sign all certificates, contracts and other instruments of the Corporation. In the absence of the Chairman,
he or she shall preside at all meetings of the stockholders. He or she shall perform all such other duties as are incident to his
or her office or are properly required of him or her by the Board of Directors.


 


(c) CHIEF FINANCIAL OFFICER: The Chief Financial
Officer shall keep or cause to be kept adequate and correct books and records of accounts of the properties and business transactions
of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings,
and shares. The books of account shall at all reasonable times be open to inspection by any Director. The Chief Financial Officer
shall (1) deposit corporate funds and other valuables in the Corporation's name and to its credit with depositories designated
by the Board of Directors; (2) make disbursements of corporate funds as authorized by the Board of Directors; (3) render a statement
of the corporation's financial condition and an account of all transactions conducted as chief financial officer whenever requested
by the President or the Board of Directors; and (4) have other powers and perform other duties as prescribed by the President or
the Board of Directors or the Bylaws. Unless the board of directors has elected a separate Treasurer, the Chief Financial Officer
shall be deemed to be the treasurer for purposes of giving any reports or executing any certificates or other documents.


 


(d) VICE PRESIDENT: Each Vice-President shall
have such powers and discharge such duties as may be assigned to him or her from time to time by the President or the Board of
Directors.


 


(e) SECRETARY AND ASSISTANT SECRETARIES: The
Secretary shall issue notices for all meetings, shall keep minutes of all meetings, shall have charge of the seal and the corporate
books, and shall make such reports and perform such other duties as are incident to his or her office, or are properly required
of him or her by the Board of Directors. The Assistant Secretary, if any, or Assistant Secretaries in order designated by the Board
of Directors, shall perform all of the duties of the Secretary during the absence or disability of the Secretary, and at other
times may perform such duties as are directed by the President or the Board of Directors.


 


Section 5.4. DELEGATION. In the case of the
absence or inability to act of any officer of the Corporation and of any person herein authorized to act in such officer's place,
the Board of Directors may from time to time delegate the powers or duties of such officer to any other officer or any Director
or other person whom it may in its sole discretion select.


 



    	 	F - 7	 



     


    

 


Section 5.5. VACANCIES. Vacancies in any office
arising from any cause may be filled by the Board of Directors at any regular or special meeting of the Board. The appointee shall
hold office for the unexpired term and until his or her successor is duly elected and qualified.


 


Section 5.6. OTHER OFFICERS. The Board of Directors,
or a duly appointed officer to whom such authority has been delegated by Board resolution, may appoint such other officers and
agents as it shall deem necessary or expedient, who shall hold their offices for such terms and shall exercise such powers and
perform such duties as shall be determined from time to time by the Board of Directors.


 


Section 5.7. RESIGNATION. An officer may resign
at any time by delivering notice to the Corporation. Such notice shall be effective when delivered unless the notice specifies
a later effective date. Any such resignation shall not affect the Corporation's contract rights, if any, with the officer.


 


Section 5.8. REMOVAL. Any officer elected or
appointed by the Board of Directors may be removed at any time, with or without cause, by the affirmative vote of a majority of
the whole Board of Directors, but such removal shall be without prejudice to the contract rights, if any, of the person so removed.


 


Section 5.9. BONDS. The Board of Directors may,
by resolution, require any and all of the officers to give bonds to the Corporation, with sufficient surety or sureties, conditioned
for the faithful performance of the duties of their respective offices, and to comply with such other conditions as may from time
to time be required by the Board of Directors.


 


ARTICLE VI 


 


CERTIFICATES OF SHARES 


 


Section 6.1. Form of Certificates. The Corporation
may, but is not required to, deliver to each stockholder a certificate or certificates, in such form as may be determined by the
Board of Directors, representing shares to which the stockholder is entitled. Such certificates shall be consecutively numbered
and shall be registered on the books and records the Corporation or its transfer agent as they are issued. Each certificate shall
state on the face thereof the holder’s name, the number, class of shares, and the par value of such shares or a statement
that such shares are without par value.


 


Section 6.2. Shares without Certificates. The
Board of Directors may authorize the issuance of uncertificated shares of some or all of the shares of any or all of its classes
or series. The issuance of uncertificated shares has no effect on existing certificates for shares until surrendered to the Corporation,
or on the respective rights and obligations of the stockholders. Unless otherwise provided by the General Corporation Law of the
State of Delaware, the rights and obligations of stockholders are identical whether or not their shares of stock are represented
by certificates. Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send the
stockholder a written statement containing the information required on the certificates pursuant to Section 6.1.


 


Section 6.3. Lost Certificates. The Board of
Directors may direct that a new certificate be issued, or that uncertificated shares be issued, in place of any certificate theretofore
issued by the Corporation alleged to have been lost or destroyed, upon the making of an affidavit of that fact by the person claiming
the certificate to be lost or destroyed. When authorizing such issue of a new certificate or uncertificated shares, the Board of
Directors, in its discretion and as a condition precedent to the issuance thereof, may require the owner of such lost or destroyed
certificate, or his legal representative, to advertise the same in such manner as it shall require and/or to give the Corporation
a bond, in such form, in such sum, and with such surety or sureties as it may direct as indemnity against any claim that may be
made against the Corporation with respect to the certificate alleged to have been lost or destroyed. When a certificate has been
lost, apparently destroyed or wrongfully taken, and the holder of record fails to notify the Corporation within a reasonable time
after he has notice of it, and the Corporation registers a transfer of the shares represented by the certificate before receiving
such notification, the holder of record is precluded from making any claim against the Corporation for the transfer or a new certificate
or uncertificated shares.


 



    	 	F - 8	 



     


    

 


Section 6.4. Transfer of Shares. Shares of stock
shall be transferable only on the books of the Corporation or its transfer agent by the holder thereof in person or by his duly
authorized attorney. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate representing shares
duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be the duty of the


 


Corporation or the transfer agent of the Corporation
to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books.


 


Section 6.5. Registered Stockholders. The Corporation
shall be entitled to treat the holder of record of any share or shares of stock as the holder in fact thereof and, accordingly,
shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person,
whether or not it shall have express or other notice thereof, except as otherwise provided by law.


 


ARTICLE VII 


 


INDEMNIFICATION 


 


Section 7.1. RIGHT TO INDEMNIFICATION. The Corporation
shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be
amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding,
whether civil, criminal, administrative or investigative (a "proceeding") by reason of the fact that he or she, or a
person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the Corporation or is
or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership,
joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability
and loss suffered and expenses (including attorneys' fees) reasonably incurred by such person. Notwithstanding the preceding sentence,
the Corporation shall be required to indemnify a person in connection with a proceeding (or part thereof) initiated by such person
only if the proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.


 


Section 7.2. PREPAYMENT OF EXPENSES. The Corporation
shall pay the expenses (including attorneys' fees) incurred in defending any proceeding in advance of its final disposition; provided,
however, that the payment of expenses incurred by a Director or officer in advance of the final disposition of the proceeding shall
be made only upon receipt of an undertaking by the Director or officer to repay all amounts advanced if it should be ultimately
determined that the Director or officer is not entitled to be indemnified under this Article VII or otherwise.


 


Section 7.3. CLAIMS. If a claim for indemnification
or payment of expenses under this Article VII is not paid in full within sixty days after a written claim therefor has been received
by the Corporation, the claimant may file suit to recover the unpaid amount of such claim and, if successful in whole or in part,
shall be entitled to be paid the expense of prosecuting such claim. In any such action the Corporation shall have the burden of
proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.


 



    	 	F - 9	 



     


    

 


Section 7.4. NON-EXCLUSIVITY OF RIGHTS. The
rights conferred on any person by this Article VII shall not be exclusive of any other rights which such person may have or hereafter
acquire under any statute, provision of the Certificate of Incorporation, these Bylaws, agreement, vote of stockholders or Directors
or otherwise.


 


Section 7.5. OTHER INDEMNIFICATION. The Corporation's
obligation, if any, to indemnify any person who was or is serving at its request as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be reduced by any amount such person may collect
as indemnification from such other corporation, partnership, joint venture, trust, enterprise or nonprofit enterprise.


 


Section 7.6. AMENDMENT OR REPEAL. Any repeal
or modification of the foregoing provisions of this Article VII shall not adversely affect any right or protection hereunder of
any person in respect of any act or omission occurring prior to the time of such repeal or modification.


 


ARTICLE VIII 


 


MISCELLANEOUS 


 


Section 8.1. FISCAL YEAR. The fiscal year of
the Corporation shall be determined by resolution of the Board of Directors. Unless otherwise determined by the Board of Directors,
the fiscal year end shall be September, 30 of each year.


 


Section 8.2. SEAL. The corporate seal shall
have the name of the Corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board
of Directors.


 


Section 8.3. WAIVER OF NOTICE OF MEETINGS OF
STOCKHOLDERS, DIRECTORS AND COMMITTEES. Any written waiver of notice, signed by the person entitled to notice, whether before or
after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver
of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the
meeting, to the transaction of any business because the meeting was not lawfully called or convened. Neither the business to be
transacted at nor the purpose of any regular or special meeting of the stockholders, Directors or members of a committee of Directors
need be specified in any written waiver of notice.


 


Section 8.4. INTERESTED DIRECTORS; QUORUM. No
contract or transaction between the Corporation and one or more of its Directors or officers, or between the Corporation and any
other corporation, partnership, association or other organization in which one or more of its Directors or officers are directors
or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the Director or
officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract
or transaction, or solely because his or her or their votes are counted for such purpose, if: (i) the material facts as to his
or her relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the
committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes
of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or (ii) the material
facts as to his or her relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders
entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or
(iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board
of Directors, a committee thereof, or the stockholders. Common or interested Directors may be counted in determining the presence
of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.


 



    	 	F - 10	 



     


    

 


Section 8.5. BOOKS AND RECORDS. The Corporation
shall maintain appropriate accounting records and shall keep as permanent records minutes of all meetings of its stockholders and
Board of Directors, a record of all actions taken by the Board of Directors without a meeting and a record of all actions taken
by a committee of the Board of Directors. In addition, the Corporation shall keep at its registered office or principal place of
business, or at the office of its transfer agent or registrar, a record of its stockholders, giving the names and addresses of
all stockholders in alphabetical order by class of shares showing the number and class of the shares held by each. Any books, records
and minutes may be in written form or any other form capable of being converted into written form within a reasonable time.


 


Section 8.6. AMENDMENT OF BYLAWS. In furtherance
and not in limitation of the powers conferred upon it by law, the Board of Directors is expressly authorized to adopt, repeal or
amend the Bylaws of the Corporation by the vote of a majority of the entire Board of Directors. The Bylaws of the Corporation shall
be subject to alteration or repeal, and new Bylaws may be made, by a majority vote of the stockholders at the time entitled to
vote in the election of Directors even though these Bylaws may also be altered, amended or repealed by the Board of Directors.


 



    	 	F - 11	 



     


    

 


Exhibit G


 


September 30, 2017 Financial Statements


 





MDNA Life Sciences

30-Sep-17

Comparative Balance Sheet 2017 – 2016


 


	 	 	As At	 	 	As At	 
	Assets	 	9/30/2017	 	 	9/30/2016	 
	 	 	 	 	 	 	 
	Cash &Cash Equivalents	 	$	59,910	 	 	$	100,616	 
	Accounts Receivables, Net	 	 	114,308	 	 	 	31,000	 
	 	 	 	-	 	 	 	-	 
	Total Current Assets	 	$	174,218	 	 	$	131,616	 
	 	 	 	 	 	 	 	 	 
	Property and Equipment	 	 	59,213	 	 	 	-	 
	Accumulated Depreciation	 	 	-	 	 	 	 	 
	Intangible Assets	 	 	16,932,220	 	 	 	16,932,220	 
	Accumulated Amortization	 	 	(1,269,917	)	 	 	(1,066,817	)
	 	 	 	 	 	 	 	 	 
	Total Other Assets	 	$	15,662,303	 	 	$	15,865,403	 
	 	 	 	 	 	 	 	 	 
	Total Other Assets	 	$	15,721,516	 	 	$	15,865,403	 
	 	 	 	 	 	 	 	 	 
	TOTAL ASSETS	 	$	15,895,734	 	 	$	15,997,019	 
	 	 	 	 	 	 	 	 	 
	LIABILITIES	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Accounts Payable	 	$	548,181	 	 	$	1,010,371	 
	Short-Term Notes Payable	 	 	3,307,180	 	 	 	2,102,358	 
	Dividends Payable	 	 	48,275	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Total Current Liabilities	 	$	3,903,636	 	 	$	3,112,729	 
	 	 	 	 	 	 	 	 	 
	Debt	 	 	 	 	 	 	 	 
	Long Term Debt	 	 	6,916,186	 	 	 	6,916,186	 
	 	 	 	 	 	 	 	 	 
	Total Liabilities	 	$	6,916,186	 	 	$	6,916,186	 
	 	 	 	 	 	 	 	 	 
	Shareholders Equity	 	 	 	 	 	 	 	 
	Common Stock	 	 	8,698,051	 	 	 	8,698,051	 
	Preferred Stock	 	 	1,514,327	 	 	 	460,000	 
	Retained Earnings	 	 	(3,818,274	)	 	 	(2,111,120	)
	Retained Earnings - Intangibles	 	 	(1,269,917	)	 	 	(1,066,817	)
	Retained Earnings - Dividends	 	 	(48,275	)	 	 	(12,010	)
	 	 	$	5,075,912	 	 	$	5,968,104	 
	 	 	 	 	 	 	 	 	 
	Total Liabilities & Equity	 	$	15,895,734	 	 	$	15,997,019	 



 


2017


 


		(A)	Short Term Payable



 


	90 Day Loans	 	$	603,000	 
	60 Day Loans	 	 	303,000	 
	Shareholder Bridge Loans	 	 	1,485,000	 
	Add'l Shareholder Bridge	 	 	429,000	 
	New Secured Loan	 	 	487,000	 
	 	 	$	3,307,000	 



 


		(B)	DEBT



 


	Long Term Debt	 	$	6,916,185	 



 


		(C)	Common Shareholders



 


	Country	 	# Holders	 	 	Shares at $1 Par	 	 	%	 
	UK/IRE	 	 	24	 	 	 	3,860,364	 	 	 	43.2	%
	CAN	 	 	36	 	 	 	2,392,864	 	 	 	26.8	%
	ROW	 	 	5	 	 	 	1,725,955	 	 	 	19.3	%
	US	 	 	19	 	 	 	718,868	 	 	 	10.7	%
	 	 	 	84	 	 	 	8,698,051	 	 	 	100.0	%
	 	 	 	Value	 	 	$	8,698,051	 	 	 	 	 



 


		(D)	Preferred Shareholders



 


	33 individulas invested - 3.8M shares	 	$	1,514,327	 
	$1.0M of $1.5M from RForte PPM	 	 	 	 



 


		(E)	Retained Earnings



 


	Net Loss 2015	 	$	986,879	 
	Net Loss 2016	 	 	1,124,241	 
	SubTotal	 	$	2,111,120	 
	Net Loss 2017	 	 	1,707,153	 
	Total	 	$	3,818,273	 



 


		(F)	Dividends Payable



 


	33 individulas are eligible for Dividends	 	$	48,275	 



 


Figures are based on latest figures loaded
into QB by Harless Accounting Adjustements to ST Payable and Cap Table developed in an Excel Schedule.







 



    	 	G - 1